
==== Front
Cell Death Discov
Cell Death Discov
Cell Death Discovery
2058-7716
Nature Publishing Group UK London

2159
10.1038/s41420-024-02159-0
Review Article
Multifaceted mitochondrial as a novel therapeutic target in dry eye: insights and interventions
Ouyang Weijie 1
http://orcid.org/0000-0003-1819-538X
Yan Dan 2
Hu Jiaoyue mydear_22000@163.com

3
Liu Zuguo zuguoliu@xmu.edu.cn

4
1 grid.452244.1 Xiamen University affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine of Xiamen University, Xiamen, Fujian, China; Department of Ophthalmology, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou China
2 https://ror.org/00mcjh785 grid.12955.3a 0000 0001 2264 7233 Xiamen University affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine of Xiamen University, Xiamen, Fujian China
3 https://ror.org/00mcjh785 grid.12955.3a 0000 0001 2264 7233 Xiamen University affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine of Xiamen University, Department of Ophthalmology of Xiang’an Hospital of Xiamen University, Xiamen, Fujian China
4 grid.461579.8 Xiamen University affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine of Xiamen University, Department of Ophthalmology of Xiang’an Hospital of Xiamen University, Xiamen, Fujian, China; Department of Ophthalmology, the First Affiliated Hospital of University of South China, University of South China, Hengyang, Hunan China
6 9 2024
6 9 2024
2024
10 39817 5 2024
20 8 2024
22 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Dry eye, recognized as the most prevalent ocular surface disorder, has risen to prominence as a significant public health issue, adversely impacting the quality of life for individuals across the globe. Despite decades of extensive research into the chronic inflammation that characterizes dry eye, the intricate mechanisms fueling this persistent inflammatory state remain incompletely understood. Among the various cellular components under investigation, mitochondria—essential for cellular energy production and homeostasis—have attracted increasing attention for their role in dry eye pathogenesis. This involvement points to mechanisms such as oxidative stress, apoptosis, and sustained inflammation, which are central to the progression of the disease. This review aims to provide a thorough exploration of mitochondrial dysfunction in dry eye, shedding light on the critical roles played by mitochondrial oxidative stress, apoptosis, and mitochondrial DNA damage. It delves into the mechanisms through which diverse pathogenic factors may trigger mitochondrial dysfunction, thereby contributing to the onset and exacerbation of dry eye. Furthermore, it lays the groundwork for an overview of current therapeutic strategies that specifically target mitochondrial dysfunction, underscoring their potential in managing this complex condition. By spotlighting this burgeoning area of research, our review seeks to catalyze the development of innovative drug discovery and therapeutic approaches. The ultimate goal is to unlock promising avenues for the future management of dry eye, potentially revolutionizing treatment paradigms and improving patient outcomes. Through this comprehensive examination, we endeavor to enrich the scientific community’s understanding of dry eye and inspire novel interventions that address the underlying mitochondrial dysfunctions contributing to this widespread disorder.

Subject terms

Eye diseases
Biomarkers
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) U20A20363 82271054 Hu Jiaoyue Liu Zuguo issue-copyright-statement© Cell Death Differentiation Association (ADMC) 2024
==== Body
pmcFacts

Dry eye is the most common ocular surface disorder, characterized by chronic inflammation.

Mitochondrial dysfunction, including oxidative stress, apoptosis, and sustained inflammation, play a critical role in the progression of dry eye.

Therapeutic strategies targeting mitochondrial dysfunction have become a burgeoning area of research in the treatment of dry eye.

Open questions

What are the exact mechanisms driving the persistent chronic inflammation in dry eye?

How do various pathogenic factors trigger mitochondrial dysfunction, and what is the relationship between these factors and the onset and severity of dry eye?

What role does mitochondria dysfunction play in dry eye?

How can we effectively target mitochondria dysfunction target mitochondrial dysfunction for therapeutic purposes?

Introduction

Dry eye (DE), identified as one of the most prevalent ocular surface diseases, manifests through tear film instability, hyperosmolarity, chronic inflammation, and a spectrum of ocular discomfort symptoms [1, 2]. The global prevalence of DE is estimated to range from 5% to 50%, positioning it as a significant public health issue worldwide [3]. Chronic inflammation plays a crucial role in the pathology of DE, where prolonged tear film instability and tear hyperosmolarity lead to epithelial cell damage [4]. Such damage triggers the release of pro-inflammatory mediators, subsequently activating antigen-presenting cells (APCs) and fostering the maturation of CD4+ T cells. These CD4+ T cells evolve into Th1 and Th17 subtypes, secreting IFN-γ and IL-17, respectively, further exacerbating epithelial cell damage and perpetuating the harmful “damage-inflammation” cycle in DE [5]. However, the initial factors triggering this chronic inflammatory cascade remain unclear, suggesting that the pathogenesis of DE involves more than just inflammatory disruptions [6].

In this context, mitochondria, serving as the cellular energy metabolism center, play vital roles in essential cellular functions such as lipid metabolism, ion balance, calcium signaling, and apoptosis [7]. Maintaining mitochondrial homeostasis is critical for preserving corneal epithelial integrity, defending against oxidative damage and inflammation, and promoting corneal epithelial migration and repair [8]. Notably, various etiological factors, including environmental stress, blue light exposure, autoimmune diseases (e.g., Sjögren’s syndrome), metabolic disorders (e.g., diabetes), and the natural aging process [3], have been linked to mitochondrial dysfunction in the development of DE. Increasing empirical evidence supports the significant role of mitochondrial dysfunction in DE [9–13], including mitochondrial oxidative stress [14], mitochondrial apoptosis [15], mitochondrial DNA (mtDNA) damage [16] and so on. Interestingly, the antioxidant agents, targeting mitochondrial dysfunction, has shown promising therapeutic effects in patients with DE [17], highlighting the potential of mitochondrial modulation as a treatment approach.

Therefore, this review meticulously examines the contribution of mitochondrial dysfunction to DE, delves into the mechanisms by which various etiological factors induce mitochondrial dysfunction leading to DE, and synthesizes current insights into the treatment of mitochondrial dysfunction in DE. We conducted a comprehensive literature search using PubMed, Web of Science, and Scopus. The keywords included “dry eye,” “mitochondrial dysfunction,” “reactive oxygen species (ROS),” “mitochondrial apoptosis,” “mitochondrial DNA (mtDNA),” and “therapy.” We included articles published in peer-reviewed journals that focused on mitochondrial dysfunction in DE, discussed therapeutic strategies targeting this dysfunction, and involved human subjects, animal models, or in vitro studies relevant to the pathophysiology and treatment of DE. We excluded articles not available in English, studies not directly related to mitochondrial dysfunction and DE, and reviews or meta-analyses lacking new empirical data. The initial search yielded numerous articles, which were then screened by titles and abstracts to identify those meeting the inclusion criteria. Full texts of potentially relevant articles were retrieved and assessed for eligibility, and reference lists of selected articles were reviewed for additional studies. Data from the included studies were extracted independently by two authors, with discrepancies resolved through discussion. The extracted data were qualitatively synthesized to provide a comprehensive overview of the current understanding of mitochondrial dysfunction in DE disease and potential therapeutic approaches. The aim is to elucidate novel therapeutic strategies and enhance understanding of the complex etiology of DE. By integrating the latest literature, this review hopes to advance the discussion on mitochondria-centered interventions, positioning mitochondrial homeostasis as a novel and critical target in the comprehensive management of DE.

Mitochondria

Mitochondria, universally acknowledged as the cellular powerhouses, harbor a distinctive dual membrane structure, complete with cristae and a unique circular genome. These organelles are not merely confined to energy production; their functions extend to calcium regulation, amino acid metabolism, and the orchestration of antiviral, apoptotic, and DNA signaling pathways [18]. At the heart of these diverse roles lies their critical function as the metabolic hub for cellular energy generation. The electron transport chain (ETC), located within the inner mitochondrial membrane (IMM), plays a pivotal role in ATP synthesis through oxidative phosphorylation (OXPHOS), supplying up to 90% of a cell’s energy needs [19, 20].

The vitality of mitochondria extends across various physiological systems, emphasizing the necessity of an intact and fully functional mitochondrial architecture for efficient energy production [21]. However, the complex structure of mitochondria makes them particularly vulnerable to external stressors [22, 23]. Such environmental challenges can compromise mitochondrial integrity, leading to redox imbalances and disruptions in their functional capabilities [24]. In the context of DE, our recent research has shed light on the profound impact of desiccation stress on mitochondrial health [25]. It was observed exacerbated mitochondrial membrane permeability and mtDNA release in corneal epithelial cells from DE mouse models, underlining the direct consequences of such stress on both mitochondrial and broader cellular molecular frameworks.

Mitochondrial microstructure and fundamental functions

Mitochondria are essential organelles responsible for various crucial functions within cells, including energy production, metabolism, and signaling [26]. A closer examination of the microstructure and fundamental functions of mitochondria highlights the intricate organization and roles of different components within these organelles. The outer membrane of mitochondria contains porins that play a vital role in facilitating ATP synthesis, protein transport, and energy transfer. Among these porins, Voltage-Dependent Anion Channels (VDAC) and the Translocase of the outer membrane (Tom) serve as critical gateways for molecules entering and exiting the mitochondria, thereby regulating essential processes [27, 28]. Within the inner membrane of mitochondria, structures known as cristae are enriched with enzymes that are crucial for ATP synthesis. These enzymes include ATP synthase, which is responsible for generating ATP, and components of the ETC, which play a key role in the process of OXPHOS to produce ATP [18, 29]. The mitochondrial matrix, a soluble component enclosed by the inner membrane, acts as a biochemical dynamo within the mitochondria. It houses essential components such as mtDNA, RNA, and various enzymes that are vital for lipid metabolism and the tricarboxylic acid (TCA) cycle, also known as the citric acid cycle or Krebs cycle [30, 31]. These components work together to carry out metabolic processes that result in the production of energy in the form of ATP. Overall, the microstructure and functions of mitochondria highlight the coordinated interplay of different components and processes that are essential for cellular energy production, metabolism, and overall cellular function.

Mitochondrial genetics and dynamics

The semi-autonomous nature of mitochondria, characterized by their own genetic material and dynamic behavior, plays a crucial role in cellular health and disease [32, 33]. mtDNA is a unique, histone-free, double-stranded circular molecule that is particularly vulnerable to mutations and damage induced by ROS [34, 35]. This susceptibility positions mitochondria as primary victims of oxidative stress, emphasizing the importance of mitochondrial integrity in cellular function. Mitochondrial dynamics, which include the processes of mitochondrial fission and fusion, are critical for maintaining cellular metabolism, supporting embryonic development, and regulating apoptosis [36, 37]. These dynamics are orchestrated by specific proteins: Mnf1, Mnf2, and OPA1 facilitate fusion, while Drp1, Fis1, Mff, and MiD49/51 are responsible for fission. The delicate balance between these two processes ensures efficient energy production and contributes to the overall health of the cell. Dysregulation of mitochondrial dynamics can significantly impair energy production efficiency, leading to detrimental effects on cellular aging [38]. This is largely due to the intimate connection between ROS production and mitochondrial integrity. As mitochondria are the main site of ROS generation during energy production, any disruption in their function or structure can exacerbate ROS levels, further damaging mtDNA and impairing mitochondrial function [39, 40]. This vicious cycle highlights the profound influence of ROS on mitochondrial energy production, consumption, and lifecycle, thereby closely linking mitochondrial dynamics to cellular bioenergetics and aging.

In essence, the intricate relationship between mitochondrial structure, function, and dynamics underscores the vital role of mitochondria in determining cellular health and susceptibility to disease. Understanding this relationship is key to unraveling the complex mechanisms underlying various pathologies and developing targeted interventions to preserve or restore mitochondrial function, potentially mitigating the effects of aging and disease.Fig. 1 Role of mitochondrial dysfunction in DE.

The risk factors for DE-induced mitochondrial dysfunction. Mitochondrial dysfunction increases intracellular ROS accumulation, activating the NLRP3 and NF-kB signaling pathways and the release of downstream inflammatory cytokines. Mitochondrial dysfunction increases mitochondrial permeability by inducing the expression of Bax. Cyt-c and DIABLO/Smac are released from mitochondria to the cytoplasm. Cyt-c binds and activates APAF-1 to form apoptotic bodies and activates Caspase-9- and Caspase-3-7-dependent apoptosis. DIABLO/Smac activates apoptosis by blocking IAP. Additionally, mtDNA can be released into the cytoplasm and recognized by pattern recognition receptors to initiate the inflammatory response.

Known Roles of mitochondrial dysfunction in DE (Fig. 1)

Mitochondrial oxidative stress in DE

Mitochondria stand as the principal metabolic centers for cellular energy, generating ATP through OXPHOS to meet the cell’s energy needs [41]. A notable byproduct of this process is the generation of ROS, primarily produced by mitochondria during normal aerobic respiration [42, 43]. Approximately 2% of electrons escape from the ETC, leading to ROS formation within the mitochondria [19]. Accumulation of intracellular ROS, stemming from mitochondrial dysfunction, can provoke cellular oxidative damage [44].

DE, a multifactorial disease, is characterized by oxidative stress within the cornea, frequently accompanied by ocular surface inflammation [45]. Both in vivo and in vitro models of DE have demonstrated ROS accumulation in corneal epithelial cells [14]. This overproduction of ROS leads to lipid peroxidation, evidenced by increased levels of toxic byproducts such as 4-hydroxy-2-nonenal (4-HNE) and malondialdehyde. The resultant imbalance between oxidase and antioxidant enzymes is marked by heightened oxidant activity of heme oxygenase 1 (HO-1) and cyclooxygenase 2 (COX2), alongside diminished antioxidant activity of superoxide dismutase 1 (SOD1) and glutathione peroxidase 1 (GPX1) [46, 47]. The mev-1 gene, encoding Cyt-1—a key component of complex II in the mitochondrial ETC—has been implicated in excessive oxidative stress associated with ocular surface epithelial damage and reduced tear production in a Tet-mev-1 conditional transgenic mouse model. Histopathological analysis revealed significant monocyte infiltration and fibrosis in the lacrimal glands of these mice, illustrating the link between mitochondrial oxidative damage and lacrimal gland dysfunction in DE [48, 49]. In addition to the primary risk factors discussed, other lifestyle-related factors such as sleep deprivation [50], mental disorders [51, 52], and unhealthy lifestyles [53] also play significant roles in the pathogenesis of dry eye disease. Sleep deprivation has been shown to increase oxidative stress and inflammatory markers, thereby worsening dry eye symptoms. Mental health conditions like depression and anxiety can alter tear production through autonomic dysregulation and medication side effects. Unhealthy lifestyle choices, including poor diet, excessive alcohol consumption, and smoking, contribute to oxidative stress and inflammation, further impacting ocular surface health. Recognizing and addressing these additional risk factors is crucial for comprehensive management of dry eye disease.

In patients with DE (both Sjögren and non-Sjögren related), elevated concentrations of lipid peroxides (LPO), myeloperoxidase (MPO), 4-HNE, MDA, and hexanoyl-lysine (HEL) have been observed in tears [54–56], with increased levels of LPO, xanthine oxidoreductase/xanthine oxidase, nitric oxide synthase (NOS2, NOS3), 4-HNE, MDA, and ROS in the conjunctival epithelium [55–60]. These oxidative markers correlate with DE severity, with variations in antioxidant enzyme expression between Sjögren and non-Sjögren related DE [61, 62].

Oxidative stress-induced ROS can activate inflammatory pathways, including NLRP3, ASC, and caspase-1, leading to increased IL-1β expression and inflammation. N-acetyl-1-cysteine (NAC) has been shown to inhibit IL-1β accumulation and expression [59, 63]. Furthermore, ROS directly triggers the NF-κB pathway [64], promoting the release of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β [65]. Reducing ROS accumulation has been demonstrated to inhibit NFκB translocation and decrease the expression of these cytokines [66], underscoring the pivotal role of oxidative stress in the pathogenesis of DE.

Mitochondrial apoptosis in DE

Mitochondrial apoptosis represents a crucial intrinsic pathway of cell death, predominantly regulated by the B-cell lymphoma 2 (Bcl-2) family proteins [67]. This family bifurcates into anti-apoptotic and pro-apoptotic groups, exemplified by Bcl-2 and Bax, respectively [68]. Located on the outer mitochondrial membrane (OMM), Bcl-2 maintains the permeability of the OMM. Upon activation of the intrinsic apoptotic pathway, expression of Bcl-2 is suppressed while that of Bax increases, leading to the opening of the permeability transition pores (PTP), enhanced mitochondrial membrane permeability, loss of mitochondrial membrane potential, and the release of apoptotic proteins such as cytochrome C (Cyt-c) and DIABLO/Smac into the cytosol. Cyt-c binds and activates APAF-1, forming the apoptosome, which in turn activates Caspase-9. Caspase-9 triggers a caspase cascade, further activating Caspase-3 and Caspase-7 to induce apoptosis. DIABLO/Smac enhances the apoptotic signal by blocking the inhibitors of apoptosis proteins (IAPs), thus activating Caspase-3, Caspase-7, and Caspase-9 [69, 70].

Extensive research has demonstrated an increase in TUNEL-positive corneal and conjunctival epithelial cells both in vivo and in vitro in DE conditions, indicating an upsurge in apoptotic cell death [71, 72]. Models of DE have shown decreased expression of Bcl-2 and increased levels of Bax, Cyt-c, and Caspase-3 [15, 73]. IFN-γ appears to play a pivotal role in mediating apoptosis within the DE context. Increased apoptotic cells, including Caspase-8 and TUNEL-positive cells, were observed in the conjunctiva of DE mice [74]. However, IFN-γ knockout mice exhibited resistance to apoptosis induced by DE. The induction of apoptosis and the production and activity of Caspase-9 in IFN-γ knockout mice subjected to DE conditions through subconjunctival injection of IFN-γ underscore the critical role of IFN-γ in regulating conjunctival cell apoptosis via dual apoptotic pathways in DE models [74]. Interestingly, IFN-γ was found to promote only the extrinsic apoptotic pathway in the cornea within the dry eye model [75].

The therapeutic significance of inhibiting the mitochondrial apoptotic pathway in dry eye treatment is underscored by studies on Cyclosporin A (CsA) [76, 77]. An increase in Caspase-3 and BAX, along with a decrease in Bcl-2, was observed in dry eye conditions. However, CsA treatment reversed these changes, highlighting the potential of targeting the mitochondrial apoptotic pathway as a therapeutic strategy in dry eye management.

Mitochondria as a platform for innate immune signaling

The human mitochondrial genome was first sequenced in 1981, containing 16,569 base pairs [78]. These genes encode various ribosomal RNAs and proteins related to the mitochondrial respiratory chain, such as Cyt-c oxidase subunits I, II, and III, as well as ATPase subunit 6. Mitochondria contain multiple copies of mtDNA, ranging from 1 to 10 copies [79]. The maintenance of mtDNA copy number facilitates mitochondrial division, allowing damaged materials to segregate into smaller mitochondria, termed as “ρ0” cells, with reduced membrane potential and increased ROS levels [80].

Due to deficiencies in mtDNA repair mechanisms, lack of histone protection, and the proximity of mtDNA to the IMM where ROS are generated, mtDNA is highly susceptible to oxidative damage [81]. ROS originating from mitochondria are considered a major cause of mtDNA damage. Additionally, factors such as UV radiation and aging exacerbate mtDNA damage, leading to diseases, particularly ocular conditions like dry eye and age-related macular disease (AMD) [82–84].

Several studies have reported an increase in 8-hydroxy-2′-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, in mtDNA in both in vivo [85, 86] and in vitro [46, 47] dry eye models. Oxidative mtDNA damage elevates 8-OHdG expression, potentially leading to NLRP3/NLRP6 imbalance, Caspase-1 activation, and release of IL-1 and IL-18 [16]. These findings suggest that oxidative mtDNA may serve as a damage-associated molecular pattern (DAMP) triggering inflammatory responses in dry eye. Elevated oxidative stress levels in mitochondria and the release of mtDNA have been observed in patients with Sjögren’s syndrome [11]. Autoimmune diseases like Sjögren’s syndrome, systemic lupus erythematosus, and rheumatoid arthritis are often associated with increased levels of circulating DNA, with the disease index of Sjögren’s syndrome correlating with circulating DNA levels [87]. Recent research has highlighted the accumulation of free DNA in the circulation of Sjögren’s syndrome patients, along with significant accumulation of mtDNA in exocrine glands, associated with NLRP3 inflammasomes and IL-18 [88]. This provides new biomarkers and therapeutic targets for Sjögren’s syndrome. Released mtDNA can be recognized by pattern recognition receptors (PRRs) such as NLRP3, TLR9, cGAS/STING, and ZBP1 to initiate inflammatory responses [11]. Given the invasive nature of Sjögren’s syndrome involving exocrine glands and the significant accumulation of mtDNA in salivary glands, it is likely that mtDNA accumulation also occurs in lacrimal glands of Sjögren’s syndrome patients. Further research is needed to confirm the role of mtDNA in lacrimal gland inflammation and dysfunction. Our latest research has revealed that in dry eye-induced ocular surface damage, the release of mtDNA from corneal epithelial cells activates the cGAS-STING signaling pathway [25]. This discovery sheds light on the connection between mitochondrial dysfunction and the development of ocular inflammation, offering a new perspective for studying the pathophysiological processes of ocular inflammatory responses.Fig. 2 Mitophagy.

In cases of DE syndrome, the condition of tear hyperosmolarity acts as a critical trigger for mitochondrial reactive oxygen species (mtROS) generation and subsequent cellular energy dysfunction. This process potentially leads to the activation of the AMP-activated protein kinase/Mitochondrial Fission Factor (AMPK/MFF) pathway in Human Corneal Epithelial Cells (HCECs). Once activated, MFF plays a pivotal role in recruiting DRP1—a cytoplasmic protein—to the OMM. This recruitment is a key step in mediating both mitochondrial fission and mitophagy, processes essential for maintaining cellular health and function under stress conditions.

Mitophagy (Fig. 2)

The balance of mitochondrial morphology and dynamics is crucial for maintaining mitochondrial homeostasis [89]. Mitochondrial dynamics involve the control of mitochondrial morphology through fission and fusion processes. Mitochondrial fragmentation or fission is a common response to stress, affecting the energy status of mitochondria and consequently influencing organelle fate [78]. Excessive fission can lead to mitochondrial damage, potentially harming cardiac, pancreatic, and neuronal cells [90]. Damaged mitochondria need to be repaired or removed to preserve cellular homeostasis. Mitophagy, a highly regulated multistep process, selectively degrades damaged or dysfunctional mitochondria. Mitochondrial fission is a prerequisite for mitophagy, as fission can promote mitophagy. Moderate autophagy helps remove damaged organelles from cells and maintain cellular homeostasis, while excessive autophagy can lead to autophagic cell death. Studies [14] using a cellular model of hyperosmotic stress have shown widespread mitochondrial fission and mitophagy in corneal epithelial cells under such conditions. Metabolic disturbances occur under hyperosmotic stress, leading to the activation of AMPK. Furthermore, AMPK activation phosphorylates MFF, which recruits DRP1 to the OMM, mediating mitochondrial fission and mitophagy. Inhibiting MFF to suppress mitochondrial fission can reverse the recurrence of dry eye syndrome.Fig. 3 Sorting mechanisms and biological effects of mitoEVs.

Potential Sorting Mechanisms in Donor Cells. The formed MDVs can be sorted into lysosomes via PINK1/Parkin, Tollip, or STX17 pathways; into peroxisomes through Vps35 and MAPL; and into the extracellular space via OPA1, SNX9, DRP1, or PINK1. In certain cases, MDVs budding from mitochondria may merge into multivesicular bodies (MVBs), subsequently being released into the extracellular space as mitochondrial EVs. Moreover, mitoEVs encompass novel EV subtypes, mitochondrial vesicles, and other potential pathways involved in mitoEV biogenesis that require further categorization. Diverse effects of these EVs in target cells. These EVs may exhibit metabolic regulatory functions, such as disruptions in mitochondrial biogenesis (e.g., AMPK, PGC1), mitochondrial respiration, and mtROS production, thereby mediating the receptor cell’s phenotypic changes (e.g., differentiation, apoptosis). MitoEVs also possess immunomodulatory functions, including the induction of pro-inflammatory signals (e.g., TLR and STING), cytokine release, IFN responses, and phagocytic activities in immune cells.

Mitochondrial transfer (Fig. 3)

In recent years, scholars have discovered that cells can form tunneling nanotubes (TNTs) to facilitate intercellular communication, enabling mitochondrial transfer between different cells to maintain metabolic balance [91]. This transfer phenomenon has been reported in many systems, including the nervous and respiratory systems. Astrocytes can transfer mitochondria to neurons, potentially providing neuroprotection and promoting neural recovery after stroke [92]. In an ischemic stroke rat model, pretreatment with melatonin for mitochondrial transfer has been found to reduce the area of brain infarction [93]. These findings suggest that intercellular mitochondrial transfer can occur under pathological conditions, where damaged mitochondria can partially restore the function of recipient cells. Previous studies have indicated that mitochondrial transport is a common intercellular mechanism that helps repair mitochondrial damage within cells [94]. The transfer of mitochondria between healthy corneal epithelial cells is typically inefficient. Hypertonic therapy can enhance the formation of TNTs and promote human mitochondrial transfer. This aligns with previous work by many researchers, indicating that stress can facilitate intercellular mitochondrial transfer, possibly related to the ability of damaged cells to emit “SOS” signals to promote such transfer. In general, mitochondrial damage serves as the primary trigger for TNT-based mitochondrial transfer [95]. However, whether this transfer contributes to the worsening damage and vicious cycle in dry eye syndrome remains unexplored. A study exploring the therapeutic effects of mesenchymal stem cells on dry eye syndrome revealed that these cells primarily improve corneal epithelial cells through mitochondrial transfer [96]. This indirectly demonstrates that mitochondrial transfer can occur in dry eyes. Live-cell imaging showing vesicles and mitochondria labeled with DiO transferring from one TM cell to another was firstly described in 2017, proving that normal and glaucomatous TM cells communicate with each other through TNTs. Literature reports suggest that vascular endothelial growth factor and hypoxia-inducible factor-1α signals can be transmitted through TNTs between malignant ovarian cancer cells and human vascular endothelial cells to write vascular endothelial growth factors [95].

Therefore, it remains to be seen whether the transfer of damaged corneal epithelial cell mitochondria leads to further damage in relatively normal cells through inflammatory promotion, oxidative stress, and related genes. Alternatively, could the transfer of mitochondria from damaged corneal epithelial cells to immune cells trigger an inflammatory response, exacerbating dry eye symptoms? These questions point towards potential future research directions.

Mitochondria OXPHOS

Mitochondrial metabolic events have been demonstrated to exert profound influences on immunological competence [97]. The primary role of mitochondria is the generation of ATP through the OXPHOS process. This metabolic activity within mitochondria significantly impacts immune responses [98, 99]. In the context of dry eye disease, innate immune responses prominently feature macrophages and dendritic cells (DCs) as key inflammatory immune cells [100, 101]. Macrophages are categorized into M1 and M2 cells, with the former associated with pro-inflammatory responses and the latter exerting regulatory functions [102]. DCs are differentiated into myeloid cells (DC1) and lymphoid-like cells (DC2). In dry eye conditions, DC2 cells primarily participate in immune regulation. The interplay between these cells and the expression of various cytokines, including interleukins and tumor necrosis factors, leads to sustained elevation of inflammatory receptor levels, culminating in dry eye syndrome [103]. Metabolic reprogramming is pivotal for dendritic cell activation and maturation. Literature indicates that active oxidative phosphorylation in mitochondria is associated with immature or tolerant DCs across multiple systemic contexts [104]. However, studies exploring the metabolic states of DCs in dry eye disease are lacking. This gap presents a novel direction for research into the pathogenic mechanisms underlying dry eye disease.

Furthermore, adaptive immunity plays a crucial role in this condition [105]. During the adaptive immune phase, the production of antigen-specific T cells in regional lymph nodes, followed by their migration to the ocular surface under stress, initiates a pathological cycle of immune responses. This includes the proliferation and expansion of T cells at the ocular surface, causing damage, reactivation of acute pro-inflammatory innate responses, and, as immune regulation is lost, a vicious cycle of pathological immune reactions [106, 107]. The quality, potential activity, and alterations in mitochondrial activity are crucial for regulating the development, fate, and function of T cells [108, 109]. Multiple studies have indicated that immunological signaling and metabolic stress directly contribute to the regulation of T cell fate and function within the tumor microenvironment, with mitochondria acting as the orchestrative hub for these molecular processes [110, 111]. Nevertheless, despite the acknowledged pathogenic role of lymphocytes in dry eye disease, the impact of mitochondrial function within these lymphocytes remains unexplored.

Risk factors for dry eye are related to mitochondrial dysfunction

Environment-related risk factors

Desiccation stress

Desiccation stress plays a crucial role in the development of dry eye. Conditions such as low humidity, high wind speed, or high temperature can easily cause excessive evaporation of tears, leading to tear hyperosmolarity. According to the findings presented in Table 1, hyperosmotic stress alters the levels of mitochondrial calcium in corneal epithelial cells, causes depolarization of the mitochondrial membrane potential, and reduces ATP synthesis, resulting in mitochondrial dysfunction [9]. This dysfunction, in turn, leads to the accumulation of ROS in corneal epithelial cells and an increase in the levels of 4-HNE and 8-OHDG [46]. On one hand, the upregulation of Bax expression results in an increase in mitochondrial membrane permeability [15]. On the other hand, oxidative mtDNA is released into the cytoplasm due to the elevated MMP, triggering innate immune responses, such as NLRP3 activation, and subsequently leading to the upregulation of inflammatory factors like IL-1 [16]. Additionally, the accumulated ROS can facilitate the translocation of NFκB, which induces the expression of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β [66].Table 1 Risk factors of DE are related to mitochondrial dysfunction.

Risk factors	Oxidative stress	Mitochondrial apoptosis	Mitochondrial DNA	Others	Ref.	
Environment-related risk factors	
Desiccation stress	ROS, 4-HNE ↑	BAX ↑	Oxidative mtDNA (8-OHDG)	Ca2+ homeostasis

ATP synthesis ↓

MMP depolarization

	[9, 15, 16, 47]	
Blue light	ROS, 4-HNE, MDA, HO-1, SOD1↑

GPX1 ↓

	BAX ↑ Bcl-2 ↓ caspase-3 ↑	Oxidative mtDNA(8-OHDG)	ATP synthesis ↓	[117–119, 121, 209–211]	
Sjögren’s syndrome	ROS, 4-HNE, HEL ↑	BAX ↑ Bcl-2 ↓ caspase-3 ↑	mtDNA release	mitochondria morphological changes,

AMA

mitophagy

	[11, 127, 212]	
Metabolic disease	
High-fat diet	ROS, NOX4, 3NT↑ malondialdehyde ↑ catalase ↑	BAX ↑	mtDNA release	Mfn2 ↓

Fis1, DRP1 ↑

	[139–141, 213]	
Diabetes	ROS, 4-HNE, 3NT↑	BAX ↑ Bcl-2 ↓	mtDNA damage

mtDNA release

	mitochondrial dynamics

mitophagy

Ca2+ homeostasis

	[147, 149, 214–216]	
Aging	ROS, HEL, 4-HNE ↑	caspase-3 ↑	8-OHdG		[153, 154]	
Benzalkonium Chloride	ROS ↑	BAX ↑ Bcl-2 ↓Cyt-c ↑		ATP synthesis ↓	[73, 158, 159]	

Blue light

DE has been increasingly associated with the prolonged use of electronic devices, particularly computers and smartphones. Research indicates that nearly half (49.5%) of individuals who frequently engage with digital screens worldwide experience symptoms of DE [112]. The primary light source in modern screens, including those of computers and mobile phones, is the light-emitting diode (LED) [113]. Notably, blue light, which is a significant optical component emitted by LEDs, is characterized as a high-energy visible light with wavelengths ranging between 400 and 500 nm [114]. This specific range of light is implicated in contributing to the discomfort and potential health risks associated with DE.

While the exact mechanisms underlying blue light-induced DE remain partially understood, a growing body of research highlights the significant impact of blue light exposure on cellular health. Blue light has been shown to trigger the production of ROS within cells, leading to oxidative damage [115–117]. This type of light exposure is particularly detrimental to mitochondrial health, manifesting as compromised mitochondrial ultrastructure, diminished rates of ATP synthesis, accumulation of ROS, and ultimately, cell death. Experimental evidence from studies where mice were exposed to equivalent doses of red, blue, and green light for ten consecutive days revealed that symptoms of ocular distress, such as increased corneal staining and reduced tear film breakup time, were uniquely observed following blue light exposure. These findings suggest a strong link between blue light exposure and oxidative damage, inflammation, and programmed cell death [118]. Further supporting this notion, studies involving human corneal and conjunctival epithelial cells have demonstrated that blue light irradiation directly contributes to the accumulation of ROS within these cells [119]. Excessive reactive oxygen species (ROS) in the cornea not only elevate the production of O2− in mitochondria and impair mitochondrial function [120], but also trigger the release of inflammatory cytokines and recruitment of macrophages. Moreover, conjunctival cells appear to be more susceptible than corneal cells. While the cornea possesses a robust antioxidative defense mechanism—blue light induces the upregulation of SOD1 in corneal epithelial cells, providing protective effects—this upregulation of SOD1 is not observed suddenly. Furthermore, the expression of GPX1 is downregulated in conjunctival epithelial cells, heightening the risk from blue light exposure [121]. Considering blue light as a risk factor for DE, it is important to recognize the conflicting evidence regarding its pathogenic effects. While in vitro and animal studies have shown that blue light can induce oxidative stress and mitochondrial dysfunction, clinical trials [122, 123], such as the one by Singh et al. [124], have found that blue light blocking lenses do not alter the signs or symptoms of eye fatigue caused by computer use. This discrepancy highlights the need for further research to understand the specific conditions under which blue light may contribute to DE pathogenesis and to identify patient populations that might benefit from blue light filtering interventions.

Sjögren’s syndrome

Sjögren’s syndrome, an autoimmune disorder primarily affecting exocrine glands, is marked by lymphocyte infiltration within these glands. This condition predominantly impacts the salivary and lacrimal glands, leading to symptoms such as dry mouth and DEs [125]. While Sjögren’s syndrome is classified as an autoimmune disease, emerging research points to a significant role of mitochondrial dysfunction in its pathogenesis. Historically, the presence of anti-mitochondrial antibodies has been noted across various autoimmune diseases, suggesting an underlying mitochondrial component [126, 127]. Specifically, in the context of Sjögren’s syndrome, patients’ salivary glands have shown signs of mitochondrial distress, including swelling of the mitochondrial matrix, loss and disintegration of cristae, and rupture of the mitochondrial membrane [11]. These mitochondrial anomalies contribute to an increase in ROS accumulation, leading to a cascade of pathological changes. A pivotal aspect of mitochondrial dysfunction in Sjögren’s syndrome is the elevation of mitochondrial ROS levels, accompanied by the release of mtDNA [11, 55]. This process triggers the activation of the NLRP3 inflammasome, culminating in the secretion of pro-inflammatory cytokines such as IL-18 [88]. Given these findings, some researchers advocate for recognizing mitochondrial dysfunction as a central inflammatory driver in Sjögren’s syndrome [128, 129]. The potential of targeting mitochondrial dysfunction as a therapeutic strategy has been underscored by studies on Metformin, an AMPK agonist. Metformin has demonstrated efficacy in enhancing salivary gland function in Sjögren’s syndrome patients by modulating mitochondrial activity [130]. This evidence positions mitochondria as a promising therapeutic target for addressing the underlying mechanisms of Sjögren’s syndrome and improving patient outcomes.

Metabolic disease

As societies have progressed, with notable improvements in living standards and quality of life, there has been a marked shift in dietary habits towards energy-dense foods rich in fats and sugars. Coupled with a decline in physical activity—attributable to the sedentary nature of many modern occupations, changes in modes of transportation, and the rise of urban living—this shift has led to a significant energy imbalance. This imbalance, characterized by a surplus of calories consumed over calories expended, is a key driver behind the increasing rates of overweight and obesity observed globally. The World Health Organization (WHO) highlighted a concerning trend in its 2016 report, noting that the global prevalence of obesity had almost tripled since 1975. By 2016, nearly 2 billion adults worldwide, or 39% of the adult population, were classified as overweight [131, 132]. Among these individuals, approximately 650 million, or 13%, were considered obese. This dramatic rise in overweight and obesity rates underscores the urgent need for public health interventions aimed at addressing this growing epidemic. The consequences of excessive energy intake extend far beyond weight gain, imposing a significant burden on various bodily organs and increasing the risk of numerous diseases. Conditions such as type 2 diabetes, fatty liver disease, hypertension, myocardial infarction, stroke, dementia, osteoarthritis, obstructive sleep apnea, and various forms of cancer are all associated with overweight and obesity [133–136].

High-fat diet

Recent research has elucidated the detrimental effects of a long-term high-fat diet on ocular health, particularly in relation to. This dietary pattern has been linked to several adverse changes within the eye, highlighting the intricate relationship between diet, mitochondrial health, and ocular function. One of the primary findings is that a long-term high-fat diet contributes to lipid accumulation in the lacrimal gland, accompanied by mitochondrial hypertrophy. These changes disrupt the normal functioning of the lacrimal gland, leading to a reduction in tear production, a key factor in the development of DE symptoms [137]. Additionally, such a diet has been shown to negatively affect the Meibomian glands, which play a crucial role in maintaining tear film stability [138]. The loss of these glands, along with duct blockages, increased oxidative stress, and heightened inflammatory responses, culminates in Meibomian gland dysfunction—a common contributor to DE disease. Moreover, a high-fat diet exacerbates oxidative stress in ocular surface epithelial cells, increasing the expression of enzymes like NOX4 and markers of nitrosative stress such as 3-nitrotyrosine (3-NT) [139]. These molecular changes lead to damage resembling DE on the ocular surface. The underlying mechanisms involve an increase in circulating free fatty acids and their abnormal deposition in tissues, necessitating their breakdown through mitochondrial β-oxidation [140]. A diet high in fats overburdens this metabolic pathway, resulting in excessive production of ROS. The accumulation of ROS not only causes mitochondrial oxidative damage but also triggers the release of inflammatory factors and activates apoptotic pathways within mitochondria [141]. Crucially, a high-fat diet disrupts mitochondrial homeostasis, tipping the balance between the dynamic processes of mitochondrial fusion and fission. Proteins such as mitofusins 1 and 2 (Mfn1 and Mfn2), optic atrophy gene 1 (OPA1), dynamin-related protein 1 (Drp1), and fission protein 1 (Fis1) are key regulators of these processes [142]. A long-term high-fat diet has been associated with a decrease in Mfn2 expression and an increase in Fis1 and Drp1 expression, signaling mitochondrial dysfunction [143]. In summary, the consumption of a long-term high-fat diet leads to mitochondrial dysfunction and elevated levels of oxidative stress, adversely affecting various ocular surface tissues. These changes collectively contribute to the development of DE, underscoring the importance of dietary choices in maintaining ocular health and preventing DE.

Diabetes

Over the last two decades, diabetes has emerged as a significant global health issue, affecting approximately 463 million adults worldwide [144]. Among the myriad complications associated with diabetes, ocular issues, particularly diabetic retinopathy—a leading cause of blindness—are prominent. Additionally, diabetes has been recognized as a risk factor for various ocular surface lesions, including DE and diabetic keratopathy [145], further establishing it as a notable cause of DE [5]. Research indicates that over half (54.3%) of individuals diagnosed with type 2 diabetes experience symptoms of DE, underscoring the profound impact of this metabolic disorder on ocular health [146].

A key aspect of the connection between type 2 diabetes and ocular complications, including DE, lies in mitochondrial dysfunction. Type 2 diabetes is characterized by alterations in mitochondrial dynamics, OXPHOS, mitophagy, and calcium homeostasis, all of which contribute to the disease’s complexity [147–149]. Specifically, high glucose levels are known to induce mitochondrial dysfunction across various tissues and organs, a condition that is also linked to the development of diabetic DE. Early stages of this condition have been associated with a reduction in tear production and lacrimal gland weight, alongside decreased oxygen consumption rates (OCR) and basal extracellular acidification rates (ECAR). Furthermore, increased mtDNA damage has been observed, with the mitochondrial bioenergetic metabolism of the lacrimal glands being significantly more impaired than that of the corneal epithelium. These findings suggest that the susceptibility of lacrimal gland bioenergetics deficiency may precipitate the early onset of DE in diabetic individuals. Interestingly, the administration of mitochondria-targeted antioxidants, such as SkQ1, has shown promise in alleviating the severity of DE by improving mitochondrial function [150]. This suggests that targeting mitochondrial dysfunction could be a viable therapeutic strategy for managing diabetic DE. The potential of mitochondria-targeted antioxidants highlights an innovative approach to treating ocular complications associated with diabetes, offering hope for improved outcomes in affected individuals.

Aging

Aging is a significant factor influencing the prevalence and severity of DE, with studies indicating a marked increase in its occurrence among individuals over the age of fifty [3]. This relationship between aging and DE can be attributed to various physiological changes that occur as part of the aging process, affecting the ocular surface and its associated glands. In aged mice, research has demonstrated several key changes that contribute to the development of DE, including disruption of corneal barrier function, heightened ocular surface inflammation [151], loss of meibomian glands [152], and increased levels of oxidative stress within the lacrimal glands [153, 154]. These findings in animal models mirror the clinical observations in humans, where similar age-related ocular changes contribute to DE symptoms. Interestingly, the relationship between aging and DE appears to be bidirectional, with DE conditions also promoting cellular senescence. Hyperosmotic stress, a condition commonly associated with DE due to tear film instability, has been shown to increase the expression of senescence markers such as p53, p21, and p16 [155]. This suggests that not only does aging predispose individuals to DE, but the presence of DE can further accelerate the aging process in ocular tissues.

A central feature of aging at the cellular level is the increased production of ROS, largely stemming from mitochondrial dysfunction. As mitochondria age, they become less efficient and more prone to releasing ROS, leading to oxidative damage [82]. This accumulation of ROS disrupts cellular signaling pathways and structural integrity [156], contributing to the aging process and the development of age-related diseases, including DE.

Benzalkonium chloride (BAC)

BAC is the most widely used preservative in ophthalmic solutions, including eye drops. Its primary role is to prevent microbial contamination during the shelf life and use of these products. Despite its antimicrobial efficacy, the long-term application of eye drops containing BAC has been associated with an increased risk of developing DE [157]. This adverse effect can be attributed to BAC’s impact on ocular surface health and underlying cellular mechanisms. Research has demonstrated that BAC exerts a concentration-dependent inhibitory effect on mitochondrial functions, specifically targeting mitochondrial complex I. This inhibition leads to a significant reduction in mitochondrial ATP production (with an IC50 of 5.3 μM) and oxygen consumption (with an IC50 of 10.9 μM), effectively impairing over 90% of mitochondrial function at certain concentrations [158]. The disruption of mitochondrial activity by BAC has profound consequences for cellular health, primarily through the induction of oxidative stress [159]. The increase in cellular oxidative stress due to BAC exposure results from an imbalance between the production of ROS and the cell’s ability to detoxify these reactive intermediates or repair the resulting damage. This oxidative stress, in turn, triggers a cascade of detrimental cellular responses, including the release of pro-inflammatory factors [160]. Moreover, BAC exposure activates the mitochondrial apoptotic pathway, a form of programmed cell death that plays a crucial role in maintaining tissue homeostasis by eliminating damaged or dysfunctional cells. The activation of this pathway is characterized by the upregulation of pro-apoptotic proteins such as Bax, inhibition of anti-apoptotic proteins like Bcl-2, and the release of Cyt-c from mitochondria into the cytosol [73, 161]. These molecular events lead to the execution phase of apoptosis, contributing to cell loss and tissue damage on the ocular surface, thereby aggravating DE symptoms.

Therapies targeting mitochondrial dysfunction

Antioxidant therapy

Nrf2 activator

Nuclear factor erythroid 2-related factor 2 (Nrf2) plays a pivotal role as a cellular antioxidant regulator, orchestrating the expression of various antioxidant response element-dependent genes. This regulation is crucial for modulating both the physiological and pathophysiological outcomes following exposure to oxidants [162]. Consequently, Nrf2 emerges as a promising antioxidant therapeutic target in the realm of DE treatment.

Research has illuminated the therapeutic potential of Nrf2 modulation in addressing DE conditions. By promoting the expression of antioxidant enzymes, such as HO-1 and GPX1, Nrf2 activation enhances cellular defense mechanisms against oxidative stress. This upregulation leads to increased ATP levels and mitochondrial membrane potential, contributing to cellular energy balance and stability. Moreover, Nrf2 activation plays a crucial role in mitigating apoptosis, primarily by inhibiting the release of Cyt-c, a key component in the apoptotic pathway. Beyond its direct antioxidant effects, Nrf2 also significantly impacts cellular resilience against oxidative damage. Enhanced Nrf2 expression has been shown to reduce intracellular ROS and diminish 8-OHdG-stained cytogenesis, markers of oxidative DNA damage [163, 164]. Furthermore, Nrf2’s regulatory capacity extends to inhibiting the ROS-NLRP3-IL-1β signaling axis, a pathway implicated in inflammatory responses. By curtailing this axis, Nrf2 offers protection against hyperosmotic stress (HS)-induced cellular damage, highlighting its integral role in combating oxidative stress and inflammation associated with DE [165].

Vitamin supplementation

Vitamins, as natural substances with antioxidant properties, have garnered significant attention for their potential role in managing DE. Numerous studies have provided evidence supporting the benefits of vitamin supplementation in the context of ocular health and DE treatment [166, 167]. One area of interest revolves around vitamin D, which has been linked to cellular responses under hypertonic conditions. Research has indicated that the levels of vitamin D and its receptor (VDR) in human corneal epithelial (HCE) cells decrease in response to hypertonic stress, suggesting a potential involvement of vitamin D in this physiological process. Furthermore, studies have demonstrated that resveratrol (RES), a polyphenolic compound with antioxidant properties, can protect against hyperosmotic stress-induced ROS production by activating Notch signaling, ultimately leading to the restoration of vitamin D levels. This interplay between RES, Notch signaling, and vitamin D highlights the complex regulatory mechanisms implicated in ocular surface health and DE pathophysiology [168]. In clinical investigations, the use of eye drops containing 0.15% hyaluronic acid and vitamin B12 has shown promising results in reducing oxidative stress levels and improving various clinical parameters associated with DE, including the Ocular Surface Disease Index (OSDI) and fluorescein tear breakup time (BUT) [57]. The observed improvements in Schirmer’s test and tear film breakup time, along with the reduction in oxidative stress, underscore the therapeutic potential of vitamin B12 in managing DE symptoms.

SKQ1

SKQ1, a mitochondria-targeting antioxidant, has shown promising therapeutic potential in the treatment of various age-related eye diseases, including cataracts, AMD, glaucoma, and DE [169, 170]. Research has indicated that SKQ1 can enhance the antioxidant activity and stability of the tear film, protecting against ROS-induced apoptosis and inflammatory responses. By mitigating these harmful processes, SKQ1 can help maintain ocular surface health and alleviate DE symptoms [171]. In an age-related DE model, SKQ1 has been found to attenuate aging-induced ultrastructural changes and restore mitochondrial numbers in the lacrimal gland. This suggests that SKQ1 may have a positive impact on cellular and tissue health in the context of DE associated with aging [172]. In the DE rats induced by benzalkonium chloride, the newly developed mitochondrial-targeted SkQ1 nanoparticles exhibited significantly higher activity in scavenging cytosolic and mitochondrial ROS. Additionally, they effectively suppressed the activation of the NLRP3 inflammasome and the inflammatory signaling mediated by NLRP3 [173]. Furthermore, SKQ1 has demonstrated improvements in diabetic DE by enhancing mitochondrial function [150]. Diabetes can adversely affect ocular health, leading to DE symptoms. SKQ1’s ability to improve mitochondrial function may contribute to its efficacy in managing DE in diabetic individuals. Clinical studies evaluating the safety and effectiveness of SKQ1 in DE treatment have reported positive outcomes. Topical application of SKQ1 eye drops 2–3 times per day for 4–6 weeks has been shown to increase tear film stability, reduce corneal fluorescein staining, and alleviate DE symptoms such as dryness, burning, foreign body sensation, and blurred vision [17, 174].

Anti-senescence drugs

Various age-related diseases are associated with decreased secretion of melatonin, suggesting an important role for melatonin in age-related diseases [175]. Melatonin has been shown to play important roles in age-related eye diseases such as glaucoma [176] and AMD [177]. Many studies have demonstrated the role of melatonin in DE. Melatonin can reduce excessive ROS production and LDH release and maintain mitochondrial function by activating HO-1 expression, reducing apoptosis and inflammatory cascades [178]. Melatonin and its derivatives can promote tear secretion by interacting with different melatonin receptors [179, 180].

Astaxanthin is a lutein carotenoid and is the most abundant carotenoid in marine life. Astaxanthin neutralizes free radicals and other oxidants by accepting or donating electrons without being destroyed or becoming a pro-oxidant in the process, with anti-senescence potential [181, 182]. Pretreatment with astaxanthin liposomes can reduce ROS generation in corneal epithelial cells and significantly inhibit the expression of the aging-related genes P53, P21, and P16 in in vivo and in vitro DE models [155, 183].

Other antioxidants

According to the key role of oxidative stress in the pathogenesis of DE, many antioxidants targeting ROS production have shown the potential of DE treatment. Eurya japonica [66], Camellia japonica [184], taurine [185], Chamaecyparis obtuse [186], KR-67607 [160], and Zidovudine [187] downregulated ROS generation in DE to reduce oxidative damage and inflammatory responses (Table 2).Table 2 Targeting to the mitochondria for treating DE.

Treatment	DE model	Mechanism	Effect	Ref.	
Edaravone	Hyperosmotic Stress	Nrf2	HO-1 ↑

GPX1 ↑

ATP ↑

ROS ↓

Cytochrome C ↓

NLRP3/IL-1β ↓ 

	[163]	
Esculetin	H2O2-treated	Nrf2	[164]	
Calcitriol	Hyperosmotic Stress	Nrf2	[165]	
RES	Hyperosmotic Stress	Notch/VDR	Vitamin D ↑

ROS ↓

	[168]	
Vitamin B12	Dry Eye Patients		ROS ↓

TBUT ↑

Tear production ↑

OSDI ↓

	[57]	
SKQ1	Ageing

Hyperglycemia

Dry Eye Patients

		Mitochondria ↑

TBUT ↑

Corneal fluorescein staining scores ↓

Symptom ↓

	[17, 150, 172, 174]	
Melatonin/ Melatonin derivative	H2O2-treated	HO-1	ROS ↓

LDH ↓

Aopotosis ↓

Inflammation ↓

Tear production ↑

	[178–180]	
Astaxanthin	Desiccating Stress

Lacrimal Glands Extraction

		ROS ↓

P53,P21,P16 ↓

	[155, 183]	
Eurya japonica	H2O2-treated

Desiccating Stress

		ROS ↓

Mitochondrial Depolarization ↑

TNF-α, IL-1β, IP-10 ↓

Tear production ↑

Corneal fluorescein staining scores ↓

	[66]	
Camellia japonica	H2O2-treated

desiccating stress

		ROS ↓

Mitochondrial Depolarization ↑

MnSOD, Catalase ↑

Corneal fluorescein staining scores ↓

IFN-γ, IL-1β, IL-6, TNF-α ↓

	[184]	
N-acetylcysteine (NAC)	Desiccating stress

4-HNE-induced

		ROS ↓

Corneal fluorescein staining scores ↓

NLRP3/IL-1β ↓ 

	[63, 217]	
Taurine	H2O2-treated

Atropine-induced

		ROS ↓

Tear production ↑

MMP-9 ↓

	[185]	
Chamaecyparis obtusa	H2O2-treated

desiccating stress

		ROS ↓

HO-1, Catalase ↑

Tear production ↑

Corneal fluorescein staining scores ↓

	[186]	
KR-67607	Benzalkonium chloride (BAC)-induced		4-HNE ↓

SOD1 ↑

IL-6, TNF-α ↓

	[160]	
Zidovudine	Hyperosmotic stress		ROS ↓

SOD1 ↑

IL-6, NF-kB ↓

	[187]	
L-Carnitine	Hyperosmotic stress		ROS, MDA, 4-HNE, 8-OHdG ↓

SOD1, GPX1, PRDX4 ↑

	[46]	
SP	Hyperosmotic stress	Akt/NK-1	Ca2+ ↑

ROS↓

glutathione ↑

Apoptosis ↓

	[218]	
α-MSH/ CMC	Hyperosmotic stress

Desiccating stress

		ROS↓

NLRP3 ↓

FL ↓

Goblet cells ↑

Tear production ↑

	[219]	
cHA-Cr-L	Hyperosmotic stress		ROS ↓

IL-1β, TNFα ↓

	[220]	
Pterostilbene	Hyperosmotic stress		ROS, MDA, 8-OHdG, COX2 ↓

SOD1, PRDX4 ↑

TNF-α, IL-1β, IL-6, MMP-2, MMP-9 ↓

	[221]	
BSP	BAC-induced

lipopolysaccharide-induced

		ROS ↓

TNFα, IL-8 ↓

Tear production ↑

	[222]	
Medicinal Plant Extracts	Desiccating stress

Dry eye patients

		4-HNE, ROS ↓

IL-1β, IL-6, TNF-α, IFN-γ ↓ 

CXCR3+ T ↓

Goblet cells ↑

OSDI ↓ BUT ↑

	[223, 224]	
Xanthan gum	H2O2-treated		ROS ↓	[225]	
Epigallocatechin gallate	Hyperosmotic Stress

IL-1β-induced

		ROS ↓pMAPK, pJNK, NFκB ↓	[226]	

Anti-mitochondrial apoptosis

Cyclosporine A (CsA) is widely recognized as a prevalent immunosuppressive agent in the management of DE. Its therapeutic action extends beyond the mere suppression of immune cell activation, delving into the realm of mitochondrial function enhancement. A pivotal aspect of CsA’s mechanism involves its direct interaction with cyclophilin D (CypD) located on the mitochondrial membrane. CypD plays a crucial role as a component of the mitochondrial permeability transition pore (mPTP), a complex that is essential for regulating mitochondrial membrane permeability and, consequently, cellular health.

The inhibition of mPTP by CsA has significant repercussions for cellular apoptosis pathways. Specifically, this inhibition leads to a reduction in the expression of Bax, a pro-apoptotic protein, and an increase in the expression of Bcl-2, an anti-apoptotic protein. The balance between these two types of proteins is critical for determining the cell’s fate, particularly in the context of apoptosis. By tipping the scales in favor of anti-apoptotic signals, CsA helps to mitigate mitochondrial apoptosis, a process that contributes to cell death and tissue damage in DE conditions.

Empirical evidence supporting the efficacy of CsA in this domain comes from studies investigating its application in DE treatment. One notable study demonstrated that topical application of CsA for a duration of 7 days led to a marked amelioration of mitochondrial apoptosis. This finding not only underscores the potential of CsA to improve cellular survival and integrity by modulating mitochondrial dynamics but also highlights its therapeutic value in addressing the underlying cellular disturbances associated with DE.

Calorie restriction (CR)

CR is clearly defined as a reduction in energy intake well below the amount of calories that would be consumed ad libitum (≥10% in human studies, usually ≥20% in rodents) [188]. This is a nutritional intervention that reduces energy intake while maintaining nutrient adequacy and has been shown to prolong healthy lifespan in rodent and primate models [189]. Substantial evidence has shown that CR benefits chronic health problems such as type 2 diabetes [190], senescence [191], cancer [192], cardiovascular disease [193, 194] and inflammatory diseases [195, 196]. CR can activate numerous endocrine and neurobiological responses ranging from the systemic level to molecular signaling pathways. Several hypotheses have been proposed regarding the mechanism by which CR promotes health, including the stress resistance hypothesis, the oxidative stress hypothesis, the altered glucose and insulin hypothesis, and the growth hormone/insulin-like growth factor-1 axis hypothesis [197, 198].

Several studies have reported the therapeutic effect of CR on age-related eye diseases [199], such as cataracts [200], uveitis [201], glaucoma [202], and fundus diseases [203–207]. Since aging and oxidative stress increase the risk of developing DE, CR is also considered to have a possible therapeutic potential for DE. After 6 months of CR, the tear volume significantly improved, and histochemical staining showed a higher density of lacrimal acinar units, a lower degree of interstitial fibrosis and reduced oxidative stress (8-OhdG and 4-HNE). Electron microscopy observation showed that the mitochondrial structure of the rat lacrimal gland was more complete after 6 months of CR. These results demonstrate that CR protects the mitochondrial structure in the lacrimal gland and mitigates oxidative stress-related damage while preserving lacrimal gland function [208].

Conclusions

This study provides a comprehensive examination of the role of mitochondrial dysfunction in DE, delving into its underlying mechanisms and the therapeutic strategies currently targeting this dysfunction. It underscores the importance of further research into mitochondrial dynamics and functions to develop more effective treatments for DE, suggesting a potential shift in therapeutic paradigms towards addressing the mitochondrial dysfunctions that contribute to this widespread condition. Mitochondrial dysfunction has emerged as a crucial factor in the pathogenesis of various diseases, including DE, highlighting the complex relationship between DE and mitochondrial dysfunction. Numerous factors leading to DE, such as environmental stress, blue light exposure, autoimmune diseases, metabolic disorders, and aging, are closely linked to mitochondrial disturbances. Despite these links, the precise mechanisms by which mitochondrial dysfunction influences DE remain complex and not fully elucidated. This gap in understanding accentuates the need for additional research into how mitochondrial dysfunction affects the development and progression of DE. Current treatments primarily focus on alleviating oxidative stress caused by mitochondrial dysfunction, yet mitochondrial impairment can result in various types of damage. This review outlines how various etiological factors might lead to mitochondrial dysfunction, thereby contributing to the onset and exacerbation of DE. These dysfunctions include mitochondrial oxidative stress, apoptosis, and DNA damage. Interestingly, treatments targeting mitochondrial dysfunction have shown promising results, highlighting the importance of mitochondrial health as a critical area for therapeutic development.

Author contributions

Weijie Ouyang: Conceptualization, methodology, methodology, validation, writing - original draft, funding acquisition. Dan Yan: Conceptualization, methodology, methodology, investigation, writing - original draft, writing - review & editing, visualization. Jiaoyue Hu: Writing - review & editing, funding acquisition, validation. Zuguo Liu: writing - review & editing, funding acquisition, validation. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by grants from the National Natural Science Foundation of China (No. 82271054, ZL; No. U20A20363, JH).

Data availability

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Weijie Ouyang, Dan Yan.
==== Refs
References

1. Chu L Wang C Zhou H Inflammation mechanism and anti-inflammatory therapy of dry eye Front Med 2024 11 1307682 10.3389/fmed.2024.1307682
Chu L, Wang C, Zhou H. Inflammation mechanism and anti-inflammatory therapy of dry eye. Front Med. 2024;11:1307682.10.3389/fmed.2024.1307682
2. Roucaute E Huertas-Bello M Sabater AL Novel treatments for dry eye syndrome Curr Opin Pharmacol 2024 75 102431 10.1016/j.coph.2024.102431 38277944
Roucaute E, Huertas-Bello M, Sabater AL. Novel treatments for dry eye syndrome. Curr Opin Pharmacol. 2024;75:102431.38277944 10.1016/j.coph.2024.102431
3. Stapleton F Alves M Bunya VY Jalbert I Lekhanont K Malet F TFOS DEWS II epidemiology report Ocul Surf 2017 15 334 65 10.1016/j.jtos.2017.05.003 28736337
Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334–65.28736337 10.1016/j.jtos.2017.05.003
4. Rao SK Mohan R Gokhale N Matalia H Mehta P Inflammation and dry eye disease-where are we? Int J Ophthalmol 2022 15 820 7 10.18240/ijo.2022.05.20 35601175
Rao SK, Mohan R, Gokhale N, Matalia H, Mehta P. Inflammation and dry eye disease-where are we? Int J Ophthalmol. 2022;15:820–7.35601175 10.18240/ijo.2022.05.20
5. Bron AJ de Paiva CS Chauhan SK Bonini S Gabison EE Jain S TFOS DEWS II pathophysiology report Ocul Surf 2017 15 438 510 10.1016/j.jtos.2017.05.011 28736340
Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510.28736340 10.1016/j.jtos.2017.05.011
6. Chovatiya R Medzhitov R Stress, inflammation, and defense of homeostasis Mol Cell 2014 54 281 8 10.1016/j.molcel.2014.03.030 24766892
Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell. 2014;54:281–8.24766892 10.1016/j.molcel.2014.03.030
7. Brooks CD Kodati B Stankowska DL Krishnamoorthy RR Role of mitophagy in ocular neurodegeneration Front Neurosci 2023 17 1299552 10.3389/fnins.2023.1299552 37965225
Brooks CD, Kodati B, Stankowska DL, Krishnamoorthy RR. Role of mitophagy in ocular neurodegeneration. Front Neurosci. 2023;17:1299552.37965225 10.3389/fnins.2023.1299552
8. Ayilam Ramachandran R Sanches JM Robertson DM The roles of autophagy and mitophagy in corneal pathology: current knowledge and future perspectives Front Med 2023 10 1064938 10.3389/fmed.2023.1064938
Ayilam Ramachandran R, Sanches JM, Robertson DM. The roles of autophagy and mitophagy in corneal pathology: current knowledge and future perspectives. Front Med. 2023;10:1064938.10.3389/fmed.2023.1064938
9. Bogdan ED Stuard WL Titone R Robertson DM IGFBP-3 mediates metabolic homeostasis during hyperosmolar stress in the corneal epithelium Investig Ophthalmol Vis Sci 2021 62 11 10.1167/iovs.62.7.11
Bogdan ED, Stuard WL, Titone R, Robertson DM. IGFBP-3 mediates metabolic homeostasis during hyperosmolar stress in the corneal epithelium. Investig Ophthalmol Vis Sci. 2021;62:11.10.1167/iovs.62.7.11
10. Tao JX Zhou WC Zhu XG Mitochondria as potential targets and initiators of the blue light hazard to the retina Oxid Med Cell Longev 2019 2019 6435364 10.1155/2019/6435364 31531186
Tao JX, Zhou WC, Zhu XG. Mitochondria as potential targets and initiators of the blue light hazard to the retina. Oxid Med Cell Longev. 2019;2019:6435364.31531186 10.1155/2019/6435364
11. Barrera MJ Aguilera S Castro I Carvajal P Jara D Molina C Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: potential role in Sjögren’s syndrome Autoimmun Rev 2021 20 102867 10.1016/j.autrev.2021.102867 34118452
Barrera MJ, Aguilera S, Castro I, Carvajal P, Jara D, Molina C, et al. Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: potential role in Sjögren’s syndrome. Autoimmun Rev. 2021;20:102867.34118452 10.1016/j.autrev.2021.102867
12. Fujimaki S, Kuwabara T. Diabetes-induced dysfunction of mitochondria and stem cells in skeletal muscle and the nervous system. Int J Mol Sci. 2017;18:2147.
13. Habiballa L Salmonowicz H Passos JF Mitochondria and cellular senescence: implications for musculoskeletal ageing Free Radic Biol Med 2019 132 3 10 10.1016/j.freeradbiomed.2018.10.417 30336251
Habiballa L, Salmonowicz H, Passos JF. Mitochondria and cellular senescence: implications for musculoskeletal ageing. Free Radic Biol Med. 2019;132:3–10.30336251 10.1016/j.freeradbiomed.2018.10.417
14. Wang B Peng L Ouyang H Wang L He D Zhong J Induction of DDIT4 impairs autophagy through oxidative stress in dry eye Investig Ophthalmol Vis Sci 2019 60 2836 47 10.1167/iovs.19-27072 31266058
Wang B, Peng L, Ouyang H, Wang L, He D, Zhong J, et al. Induction of DDIT4 impairs autophagy through oxidative stress in dry eye. Investig Ophthalmol Vis Sci. 2019;60:2836–47.31266058 10.1167/iovs.19-27072
15. Park B, Lee IS, Hyun SW, Jo K, Lee TG, Kim JS, et al. The protective effect of Polygonum cuspidatum (PCE) aqueous extract in a dry eye model. Nutrients. 2018;10:1550–65.
16. Chi W Hua X Chen X Bian F Yuan X Zhang L Mitochondrial DNA oxidation induces imbalanced activity of NLRP3/NLRP6 inflammasomes by activation of caspase-8 and BRCC36 in dry eye J Autoimmun 2017 80 65 76 10.1016/j.jaut.2017.02.006 28238526
Chi W, Hua X, Chen X, Bian F, Yuan X, Zhang L, et al. Mitochondrial DNA oxidation induces imbalanced activity of NLRP3/NLRP6 inflammasomes by activation of caspase-8 and BRCC36 in dry eye. J Autoimmun. 2017;80:65–76.28238526 10.1016/j.jaut.2017.02.006
17. Brzheskiy VV Efimova EL Vorontsova TN Alekseev VN Gusarevich OG Shaidurova KN Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of visomitin eye drops in patients with dry eye syndrome Adv Ther 2015 32 1263 79 10.1007/s12325-015-0273-6 26660938
Brzheskiy VV, Efimova EL, Vorontsova TN, Alekseev VN, Gusarevich OG, Shaidurova KN, et al. Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of visomitin eye drops in patients with dry eye syndrome. Adv Ther. 2015;32:1263–79.26660938 10.1007/s12325-015-0273-6
18. Monzel AS Enríquez JA Picard M Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction Nat Metab 2023 5 546 62 10.1038/s42255-023-00783-1 37100996
Monzel AS, Enríquez JA, Picard M. Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction. Nat Metab. 2023;5:546–62.37100996 10.1038/s42255-023-00783-1
19. Oyewole AO Birch-Machin MA Mitochondria-targeted antioxidants FASEB J 2015 29 4766 71 10.1096/fj.15-275404 26253366
Oyewole AO, Birch-Machin MA. Mitochondria-targeted antioxidants. FASEB J. 2015;29:4766–71.26253366 10.1096/fj.15-275404
20. Nunnari J Suomalainen A Mitochondria: in sickness and in health Cell 2012 148 1145 59 10.1016/j.cell.2012.02.035 22424226
Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148:1145–59.22424226 10.1016/j.cell.2012.02.035
21. Annesley SJ, Fisher PR. Mitochondria in health and disease. Cells. 2019;8:680–87.
22. Pickles S Vigié P Youle RJ Mitophagy and quality control mechanisms in mitochondrial maintenance Curr Biol 2018 28 R170 r85 10.1016/j.cub.2018.01.004 29462587
Pickles S, Vigié P, Youle RJ. Mitophagy and quality control mechanisms in mitochondrial maintenance. Curr Biol. 2018;28:R170–r85.29462587 10.1016/j.cub.2018.01.004
23. Amorim JA Coppotelli G Rolo AP Palmeira CM Ross JM Sinclair DA Mitochondrial and metabolic dysfunction in ageing and age-related diseases Nat Rev Endocrinol 2022 18 243 58 10.1038/s41574-021-00626-7 35145250
Amorim JA, Coppotelli G, Rolo AP, Palmeira CM, Ross JM, Sinclair DA. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat Rev Endocrinol. 2022;18:243–58.35145250 10.1038/s41574-021-00626-7
24. Cheng YW Liu J Finkel T Mitohormesis Cell Metab 2023 35 1872 86 10.1016/j.cmet.2023.10.011 37939657
Cheng YW, Liu J, Finkel T. Mitohormesis. Cell Metab. 2023;35:1872–86.37939657 10.1016/j.cmet.2023.10.011
25. Ouyang W Wang S Yan D Wu J Zhang Y Li W The cGAS-STING pathway-dependent sensing of mitochondrial DNA mediates ocular surface inflammation Signal Transduct Target Ther 2023 8 371 10.1038/s41392-023-01624-z 37735446
Ouyang W, Wang S, Yan D, Wu J, Zhang Y, Li W, et al. The cGAS-STING pathway-dependent sensing of mitochondrial DNA mediates ocular surface inflammation. Signal Transduct Target Ther. 2023;8:371.37735446 10.1038/s41392-023-01624-z
26. Liu Y, Huang Y, Xu C, An P, Luo Y, Jiao L, et al. Mitochondrial dysfunction and therapeutic perspectives in cardiovascular diseases. Int J Mol Sci. 2022;23:16053.
27. Mito T Vincent AE Faitg J Taylor RW Khan NA McWilliams TG Mosaic dysfunction of mitophagy in mitochondrial muscle disease Cell Metab 2022 34 197 208.e5 10.1016/j.cmet.2021.12.017 35030325
Mito T, Vincent AE, Faitg J, Taylor RW, Khan NA, McWilliams TG, et al. Mosaic dysfunction of mitophagy in mitochondrial muscle disease. Cell Metab. 2022;34:197–208.e5.35030325 10.1016/j.cmet.2021.12.017
28. Zhao Y, Zhou Y, Wang D, Huang Z, Xiao X, Zheng Q, et al. Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD). Int J Mol Sci. 2023;24:17514.
29. Adebayo M Singh S Singh AP Dasgupta S Mitochondrial fusion and fission: the fine-tune balance for cellular homeostasis Faseb j 2021 35 e21620 10.1096/fj.202100067R 34048084
Adebayo M, Singh S, Singh AP, Dasgupta S. Mitochondrial fusion and fission: the fine-tune balance for cellular homeostasis. Faseb j. 2021;35:e21620.34048084 10.1096/fj.202100067R
30. Choong CJ Okuno T Ikenaka K Baba K Hayakawa H Koike M Alternative mitochondrial quality control mediated by extracellular release Autophagy 2021 17 2962 74 10.1080/15548627.2020.1848130 33218272
Choong CJ, Okuno T, Ikenaka K, Baba K, Hayakawa H, Koike M, et al. Alternative mitochondrial quality control mediated by extracellular release. Autophagy. 2021;17:2962–74.33218272 10.1080/15548627.2020.1848130
31. Rossmann MP, Dubois SM, Agarwal S, Zon LI. Mitochondrial function in development and disease. Dis Model Mech. 2021;14:dmm048912.
32. Nadalutti CA Ayala-Peña S Santos JH Mitochondrial DNA damage as driver of cellular outcomes Am J Physiol Cell Physiol 2022 322 C136 c50 10.1152/ajpcell.00389.2021 34936503
Nadalutti CA, Ayala-Peña S, Santos JH. Mitochondrial DNA damage as driver of cellular outcomes. Am J Physiol Cell Physiol. 2022;322:C136–c50.34936503 10.1152/ajpcell.00389.2021
33. Busch JD Fielden LF Pfanner N Wiedemann N Mitochondrial protein transport: versatility of translocases and mechanisms Mol Cell 2023 83 890 910 10.1016/j.molcel.2023.02.020 36931257
Busch JD, Fielden LF, Pfanner N, Wiedemann N. Mitochondrial protein transport: versatility of translocases and mechanisms. Mol Cell. 2023;83:890–910.36931257 10.1016/j.molcel.2023.02.020
34. Beikoghli Kalkhoran S, Kararigas G. Oestrogenic regulation of mitochondrial dynamics. Int J Mol Sci. 2022;23:1118.
35. Huang T Zhang T Gao J Targeted mitochondrial delivery: a therapeutic new era for disease treatment J Control Release 2022 343 89 106 10.1016/j.jconrel.2022.01.025 35077740
Huang T, Zhang T, Gao J. Targeted mitochondrial delivery: a therapeutic new era for disease treatment. J Control Release. 2022;343:89–106.35077740 10.1016/j.jconrel.2022.01.025
36. Chan DC Mitochondrial dynamics and its involvement in disease Annu Rev Pathol 2020 15 235 59 10.1146/annurev-pathmechdis-012419-032711 31585519
Chan DC. Mitochondrial dynamics and its involvement in disease. Annu Rev Pathol. 2020;15:235–59.31585519 10.1146/annurev-pathmechdis-012419-032711
37. Giacomello M Pyakurel A Glytsou C Scorrano L The cell biology of mitochondrial membrane dynamics Nat Rev Mol Cell Biol 2020 21 204 24 10.1038/s41580-020-0210-7 32071438
Giacomello M, Pyakurel A, Glytsou C, Scorrano L. The cell biology of mitochondrial membrane dynamics. Nat Rev Mol Cell Biol. 2020;21:204–24.32071438 10.1038/s41580-020-0210-7
38. Quintana-Cabrera R Scorrano L Determinants and outcomes of mitochondrial dynamics Mol Cell 2023 83 857 76 10.1016/j.molcel.2023.02.012 36889315
Quintana-Cabrera R, Scorrano L. Determinants and outcomes of mitochondrial dynamics. Mol Cell. 2023;83:857–76.36889315 10.1016/j.molcel.2023.02.012
39. Chen W Zhao H Li Y Mitochondrial dynamics in health and disease: mechanisms and potential targets Signal Transduct Target Ther 2023 8 333 10.1038/s41392-023-01547-9 37669960
Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct Target Ther. 2023;8:333.37669960 10.1038/s41392-023-01547-9
40. Zacharioudakis E Gavathiotis E Mitochondrial dynamics proteins as emerging drug targets Trends Pharmacol Sci 2023 44 112 27 10.1016/j.tips.2022.11.004 36496299
Zacharioudakis E, Gavathiotis E. Mitochondrial dynamics proteins as emerging drug targets. Trends Pharmacol Sci. 2023;44:112–27.36496299 10.1016/j.tips.2022.11.004
41. Valenti D, Atlante A. Mitochondrial bioenergetics in different pathophysiological conditions. Int J Mol Sci. 2021;22:7562.
42. Castellanos E Lanning NJ Phosphorylation of OXPHOS machinery subunits: functional implications in cell biology and disease Yale J Biol Med 2019 92 523 31 31543713
Castellanos E, Lanning NJ. Phosphorylation of OXPHOS machinery subunits: functional implications in cell biology and disease. Yale J Biol Med. 2019;92:523–31.31543713
43. Shimura T. ATM-mediated mitochondrial radiation responses of human fibroblasts. Genes. 2021;12:1015.
44. Esposito LA Melov S Panov A Cottrell BA Wallace DC Mitochondrial disease in mouse results in increased oxidative stress Proc Natl Acad Sci USA 1999 96 4820 5 10.1073/pnas.96.9.4820 10220377
Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci USA. 1999;96:4820–5.10220377 10.1073/pnas.96.9.4820
45. Sheppard J Shen Lee B Periman LM Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists Ann Med 2023 55 241 52 10.1080/07853890.2022.2157477 36576348
Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023;55:241–52.36576348 10.1080/07853890.2022.2157477
46. Hua X Deng R Li J Chi W Su Z Lin J Protective effects of L-carnitine against oxidative injury by hyperosmolarity in human corneal epithelial cells Investig Ophthalmol Vis Sci 2015 56 5503 11 10.1167/iovs.14-16247 26284556
Hua X, Deng R, Li J, Chi W, Su Z, Lin J, et al. Protective effects of L-carnitine against oxidative injury by hyperosmolarity in human corneal epithelial cells. Investig Ophthalmol Vis Sci. 2015;56:5503–11.26284556 10.1167/iovs.14-16247
47. Deng R Hua X Li J Chi W Zhang Z Lu F Oxidative stress markers induced by hyperosmolarity in primary human corneal epithelial cells PLoS ONE 2015 10 e0126561 10.1371/journal.pone.0126561 26024535
Deng R, Hua X, Li J, Chi W, Zhang Z, Lu F, et al. Oxidative stress markers induced by hyperosmolarity in primary human corneal epithelial cells. PLoS ONE. 2015;10:e0126561.26024535 10.1371/journal.pone.0126561
48. Uchino Y Kawakita T Ishii T Ishii N Tsubota K A new mouse model of dry eye disease: oxidative stress affects functional decline in the lacrimal gland Cornea 2012 31 S63 7 10.1097/ICO.0b013e31826a5de1 23038038
Uchino Y, Kawakita T, Ishii T, Ishii N, Tsubota K. A new mouse model of dry eye disease: oxidative stress affects functional decline in the lacrimal gland. Cornea. 2012;31:S63–7.23038038 10.1097/ICO.0b013e31826a5de1
49. Uchino Y Kawakita T Miyazawa M Ishii T Onouchi H Yasuda K Oxidative stress induced inflammation initiates functional decline of tear production PLoS ONE 2012 7 e45805 10.1371/journal.pone.0045805 23071526
Uchino Y, Kawakita T, Miyazawa M, Ishii T, Onouchi H, Yasuda K, et al. Oxidative stress induced inflammation initiates functional decline of tear production. PLoS ONE. 2012;7:e45805.23071526 10.1371/journal.pone.0045805
50. Li S Ning K Zhou J Guo Y Zhang H Zhu Y Sleep deprivation disrupts the lacrimal system and induces dry eye disease Exp Mol Med 2018 50 e451 e 10.1038/emm.2017.285 29497171
Li S, Ning K, Zhou J, Guo Y, Zhang H, Zhu Y, et al. Sleep deprivation disrupts the lacrimal system and induces dry eye disease. Exp Mol Med. 2018;50:e451–e.29497171 10.1038/emm.2017.285
51. An Y Kim H Sleep disorders, mental health, and dry eye disease in South Korea Sci Rep 2022 12 11046 10.1038/s41598-022-14167-0 35773440
An Y, Kim H. Sleep disorders, mental health, and dry eye disease in South Korea. Sci Rep. 2022;12:11046.35773440 10.1038/s41598-022-14167-0
52. Basilious A Xu CY Malvankar-Mehta MS Dry eye disease and psychiatric disorders: a systematic review and meta-analysis Eur J Ophthalmol 2022 32 1872 89 10.1177/11206721211060963 34935549
Basilious A, Xu CY, Malvankar-Mehta MS. Dry eye disease and psychiatric disorders: a systematic review and meta-analysis. Eur J Ophthalmol. 2022;32:1872–89.34935549 10.1177/11206721211060963
53. Wang MT Muntz A Mamidi B Wolffsohn JS Craig JP Modifiable lifestyle risk factors for dry eye disease Contact Lens Anterior Eye 2021 44 101409 10.1016/j.clae.2021.01.004 33485806
Wang MT, Muntz A, Mamidi B, Wolffsohn JS, Craig JP. Modifiable lifestyle risk factors for dry eye disease. Contact Lens Anterior Eye. 2021;44:101409.33485806 10.1016/j.clae.2021.01.004
54. Augustin AJ Spitznas M Kaviani N Meller D Koch FH Grus F Oxidative reactions in the tear fluid of patients suffering from dry eyes Graefes Arch Clin Exp Ophthalmol 1995 233 694 8 10.1007/BF00164671 8566825
Augustin AJ, Spitznas M, Kaviani N, Meller D, Koch FH, Grus F, et al. Oxidative reactions in the tear fluid of patients suffering from dry eyes. Graefes Arch Clin Exp Ophthalmol. 1995;233:694–8.8566825 10.1007/BF00164671
55. Wakamatsu TH Dogru M Matsumoto Y Kojima T Kaido M Ibrahim OM Evaluation of lipid oxidative stress status in Sjogren syndrome patients Invest Ophthalmol Vis Sci 2013 54 201 10 10.1167/iovs.12-10325 23150615
Wakamatsu TH, Dogru M, Matsumoto Y, Kojima T, Kaido M, Ibrahim OM, et al. Evaluation of lipid oxidative stress status in Sjogren syndrome patients. Invest Ophthalmol Vis Sci. 2013;54:201–10.23150615 10.1167/iovs.12-10325
56. Choi W Lian C Ying L Kim GE You IC Park SH Expression of lipid peroxidation markers in the tear film and ocular surface of patients with non-sjogren syndrome: potential biomarkers for dry eye disease Curr Eye Res 2016 41 1143 9 10.3109/02713683.2015.1098707 26731289
Choi W, Lian C, Ying L, Kim GE, You IC, Park SH, et al. Expression of lipid peroxidation markers in the tear film and ocular surface of patients with non-sjogren syndrome: potential biomarkers for dry eye disease. Curr Eye Res. 2016;41:1143–9.26731289 10.3109/02713683.2015.1098707
57. Macri A Scanarotti C Bassi AM Giuffrida S Sangalli G Traverso CE Evaluation of oxidative stress levels in the conjunctival epithelium of patients with or without dry eye, and dry eye patients treated with preservative-free hyaluronic acid 0.15% and vitamin B12 eye drops Graefes Arch Clin Exp Ophthalmol 2015 253 425 30 10.1007/s00417-014-2853-6 25398660
Macri A, Scanarotti C, Bassi AM, Giuffrida S, Sangalli G, Traverso CE, et al. Evaluation of oxidative stress levels in the conjunctival epithelium of patients with or without dry eye, and dry eye patients treated with preservative-free hyaluronic acid 0.15% and vitamin B12 eye drops. Graefes Arch Clin Exp Ophthalmol. 2015;253:425–30.25398660 10.1007/s00417-014-2853-6
58. Cejkova J Ardan T Simonova Z Cejka C Malec J Jirsova K Nitric oxide synthase induction and cytotoxic nitrogen-related oxidant formation in conjunctival epithelium of dry eye (Sjogren’s syndrome) Nitric Oxide 2007 17 10 7 10.1016/j.niox.2007.04.006 17600738
Cejkova J, Ardan T, Simonova Z, Cejka C, Malec J, Jirsova K, et al. Nitric oxide synthase induction and cytotoxic nitrogen-related oxidant formation in conjunctival epithelium of dry eye (Sjogren’s syndrome). Nitric Oxide. 2007;17:10–7.17600738 10.1016/j.niox.2007.04.006
59. Zheng Q Ren Y Reinach PS Xiao B Lu H Zhu Y Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients Exp Eye Res 2015 134 133 40 10.1016/j.exer.2015.02.013 25701684
Zheng Q, Ren Y, Reinach PS, Xiao B, Lu H, Zhu Y, et al. Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients. Exp Eye Res. 2015;134:133–40.25701684 10.1016/j.exer.2015.02.013
60. Cejkova J Ardan T Jirsova K Jechova G Malec J Simonova Z The role of conjunctival epithelial cell xanthine oxidoreductase/xanthine oxidase in oxidative reactions on the ocular surface of dry eye patients with Sjogren’s syndrome Histol Histopathol 2007 22 997 1003 17523077
Cejkova J, Ardan T, Jirsova K, Jechova G, Malec J, Simonova Z, et al. The role of conjunctival epithelial cell xanthine oxidoreductase/xanthine oxidase in oxidative reactions on the ocular surface of dry eye patients with Sjogren’s syndrome. Histol Histopathol. 2007;22:997–1003.17523077
61. Cejkova J Ardan T Simonova Z Cejka C Malec J Dotrelova D Decreased expression of antioxidant enzymes in the conjunctival epithelium of dry eye (Sjogren’s syndrome) and its possible contribution to the development of ocular surface oxidative injuries Histol Histopathol 2008 23 1477 83 18830933
Cejkova J, Ardan T, Simonova Z, Cejka C, Malec J, Dotrelova D, et al. Decreased expression of antioxidant enzymes in the conjunctival epithelium of dry eye (Sjogren’s syndrome) and its possible contribution to the development of ocular surface oxidative injuries. Histol Histopathol. 2008;23:1477–83.18830933
62. Soria J Duran JA Etxebarria J Merayo J Gonzalez N Reigada R Tear proteome and protein network analyses reveal a novel pentamarker panel for tear film characterization in dry eye and meibomian gland dysfunction J Proteom 2013 78 94 112 10.1016/j.jprot.2012.11.017
Soria J, Duran JA, Etxebarria J, Merayo J, Gonzalez N, Reigada R, et al. Tear proteome and protein network analyses reveal a novel pentamarker panel for tear film characterization in dry eye and meibomian gland dysfunction. J Proteom. 2013;78:94–112.10.1016/j.jprot.2012.11.017
63. Zheng Q Ren Y Reinach PS She Y Xiao B Hua S Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye Exp Eye Res 2014 125 1 8 10.1016/j.exer.2014.05.001 24836981
Zheng Q, Ren Y, Reinach PS, She Y, Xiao B, Hua S, et al. Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye. Exp Eye Res. 2014;125:1–8.24836981 10.1016/j.exer.2014.05.001
64. Lu QB Wan MY Wang PY Zhang CX Xu DY Liao X Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFkappaB/mTOR/P70S6K signaling cascade Redox Biol 2018 14 656 68 10.1016/j.redox.2017.11.012 29175753
Lu QB, Wan MY, Wang PY, Zhang CX, Xu DY, Liao X, et al. Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFkappaB/mTOR/P70S6K signaling cascade. Redox Biol. 2018;14:656–68.29175753 10.1016/j.redox.2017.11.012
65. Yang Y Huang C Lin X Wu Y Ouyang W Tang L 0.005% Preservative-free latanoprost induces dry eye-like ocular surface damage via promotion of inflammation in mice Investig Ophthalmol Vis Sci 2018 59 3375 84 10.1167/iovs.18-24013 30025085
Yang Y, Huang C, Lin X, Wu Y, Ouyang W, Tang L, et al. 0.005% Preservative-free latanoprost induces dry eye-like ocular surface damage via promotion of inflammation in mice. Investig Ophthalmol Vis Sci. 2018;59:3375–84.30025085 10.1167/iovs.18-24013
66. Li L Jin R Li Y Nho JH Choi W Ji YS Effects of Eurya japonica extracts on human corneal epithelial cells and experimental dry eye Exp Ther Med 2020 20 1607 15 10.3892/etm.2020.8830 32742392
Li L, Jin R, Li Y, Nho JH, Choi W, Ji YS, et al. Effects of Eurya japonica extracts on human corneal epithelial cells and experimental dry eye. Exp Ther Med. 2020;20:1607–15.32742392 10.3892/etm.2020.8830
67. Morris JL, Gillet G, Prudent J, Popgeorgiev N. Bcl-2 family of proteins in the control of mitochondrial calcium signalling: an old chap with new roles. Int J Mol Sci. 2021;22:3730.
68. Wong WW Puthalakath H Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway IUBMB Life 2008 60 390 7 10.1002/iub.51 18425793
Wong WW, Puthalakath H. Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB Life. 2008;60:390–7.18425793 10.1002/iub.51
69. Ashkenazi A Salvesen G Regulated cell death: signaling and mechanisms Annu Rev Cell Dev Biol 2014 30 337 56 10.1146/annurev-cellbio-100913-013226 25150011
Ashkenazi A, Salvesen G. Regulated cell death: signaling and mechanisms. Annu Rev Cell Dev Biol. 2014;30:337–56.25150011 10.1146/annurev-cellbio-100913-013226
70. Pan Y Cheng A Wang M Yin Z Jia R The dual regulation of apoptosis by flavivirus Front Microbiol 2021 12 654494 10.3389/fmicb.2021.654494 33841381
Pan Y, Cheng A, Wang M, Yin Z, Jia R. The dual regulation of apoptosis by flavivirus. Front Microbiol. 2021;12:654494.33841381 10.3389/fmicb.2021.654494
71. Zhang X Lin X Liu Z Wu Y Yang Y Ouyang W Topical application of mizoribine suppresses CD4+ T-cell-mediated pathogenesis in murine dry eye Investig Ophthalmol Vis Sci 2017 58 6056 64 10.1167/iovs.17-22852 29204644
Zhang X, Lin X, Liu Z, Wu Y, Yang Y, Ouyang W, et al. Topical application of mizoribine suppresses CD4+ T-cell-mediated pathogenesis in murine dry eye. Investig Ophthalmol Vis Sci. 2017;58:6056–64.29204644 10.1167/iovs.17-22852
72. Park JH Moon SH Kang DH Um HJ Kang SS Kim JY Diquafosol sodium inhibits apoptosis and inflammation of corneal epithelial cells via activation of Erk1/2 and RSK: in vitro and in vivo dry eye model Investig Ophthalmol Vis Sci 2018 59 5108 15 10.1167/iovs.17-22925 30372737
Park JH, Moon SH, Kang DH, Um HJ, Kang SS, Kim JY, et al. Diquafosol sodium inhibits apoptosis and inflammation of corneal epithelial cells via activation of Erk1/2 and RSK: in vitro and in vivo dry eye model. Investig Ophthalmol Vis Sci. 2018;59:5108–15.30372737 10.1167/iovs.17-22925
73. Kang SW Kim KA Lee CH Yang SJ Kang TK Jung JH A standardized extract of Rhynchosia volubilis Lour. exerts a protective effect on benzalkonium chloride-induced mouse dry eye model J Ethnopharmacol 2018 215 91 100 10.1016/j.jep.2017.12.041 29288830
Kang SW, Kim KA, Lee CH, Yang SJ, Kang TK, Jung JH, et al. A standardized extract of Rhynchosia volubilis Lour. exerts a protective effect on benzalkonium chloride-induced mouse dry eye model. J Ethnopharmacol. 2018;215:91–100.29288830 10.1016/j.jep.2017.12.041
74. Zhang X Chen W De Paiva CS Corrales RM Volpe EA McClellan AJ Interferon-gamma exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways Invest Ophthalmol Vis Sci 2011 52 6279 85 10.1167/iovs.10-7081 21474767
Zhang X, Chen W, De Paiva CS, Corrales RM, Volpe EA, McClellan AJ, et al. Interferon-gamma exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Invest Ophthalmol Vis Sci. 2011;52:6279–85.21474767 10.1167/iovs.10-7081
75. Zhang X Chen W De Paiva CS Volpe EA Gandhi NB Farley WJ Desiccating stress induces CD4+ T-cell-mediated Sjogren’s syndrome-like corneal epithelial apoptosis via activation of the extrinsic apoptotic pathway by interferon-gamma Am J Pathol 2011 179 1807 14 10.1016/j.ajpath.2011.06.030 21843497
Zhang X, Chen W, De Paiva CS, Volpe EA, Gandhi NB, Farley WJ, et al. Desiccating stress induces CD4+ T-cell-mediated Sjogren’s syndrome-like corneal epithelial apoptosis via activation of the extrinsic apoptotic pathway by interferon-gamma. Am J Pathol. 2011;179:1807–14.21843497 10.1016/j.ajpath.2011.06.030
76. Sun J Wang J Cyclosporine inhibits apoptosis in experimental murine xerophthalamia conjunctival epithelium J Huazhong Univ Sci Technol Med Sci 2006 26 469 71 10.1007/s11596-006-0424-8
Sun J, Wang J. Cyclosporine inhibits apoptosis in experimental murine xerophthalamia conjunctival epithelium. J Huazhong Univ Sci Technol Med Sci. 2006;26:469–71.10.1007/s11596-006-0424-8
77. Gao J Schwalb TA Addeo JV Ghosn CR Stern ME The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy Cornea 1998 17 654 63 10.1097/00003226-199811000-00014 9820947
Gao J, Schwalb TA, Addeo JV, Ghosn CR, Stern ME. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Cornea. 1998;17:654–63.9820947 10.1097/00003226-199811000-00014
78. Anderson S Bankier AT Barrell BG de Bruijn MH Coulson AR Drouin J Sequence and organization of the human mitochondrial genome Nature 1981 290 457 65 10.1038/290457a0 7219534
Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, et al. Sequence and organization of the human mitochondrial genome. Nature. 1981;290:457–65.7219534 10.1038/290457a0
79. Satoh M Kuroiwa T Organization of multiple nucleoids and DNA molecules in mitochondria of a human cell Exp Cell Res 1991 196 137 40 10.1016/0014-4827(91)90467-9 1715276
Satoh M, Kuroiwa T. Organization of multiple nucleoids and DNA molecules in mitochondria of a human cell. Exp Cell Res. 1991;196:137–40.1715276 10.1016/0014-4827(91)90467-9
80. Kleele T Rey T Winter J Zaganelli S Mahecic D Perreten Lambert H Distinct fission signatures predict mitochondrial degradation or biogenesis Nature 2021 593 435 9 10.1038/s41586-021-03510-6 33953403
Kleele T, Rey T, Winter J, Zaganelli S, Mahecic D, Perreten Lambert H, et al. Distinct fission signatures predict mitochondrial degradation or biogenesis. Nature. 2021;593:435–9.33953403 10.1038/s41586-021-03510-6
81. Akhmedov AT Marin-Garcia J Mitochondrial DNA maintenance: an appraisal Mol Cell Biochem 2015 409 283 305 10.1007/s11010-015-2532-x 26286847
Akhmedov AT, Marin-Garcia J. Mitochondrial DNA maintenance: an appraisal. Mol Cell Biochem. 2015;409:283–305.26286847 10.1007/s11010-015-2532-x
82. Saccà SC, Cutolo CA, Ferrari D, Corazza P, Traverso CE. The eye, oxidative damage and polyunsaturated fatty acids. Nutrients. 2018;10:668.
83. Mecocci P MacGarvey U Kaufman AE Koontz D Shoffner JM Wallace DC Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain Ann Neurol 1993 34 609 16 10.1002/ana.410340416 8215249
Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol. 1993;34:609–16.8215249 10.1002/ana.410340416
84. Barja G Free radicals and aging Trends Neurosci 2004 27 595 600 10.1016/j.tins.2004.07.005 15374670
Barja G. Free radicals and aging. Trends Neurosci. 2004;27:595–600.15374670 10.1016/j.tins.2004.07.005
85. Ohguchi T Kojima T Ibrahim OM Nagata T Shimizu T Shirasawa T The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice Investig Ophthalmol Vis Sci 2013 54 7793 802 10.1167/iovs.13-13128 24168989
Ohguchi T, Kojima T, Ibrahim OM, Nagata T, Shimizu T, Shirasawa T, et al. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice. Investig Ophthalmol Vis Sci. 2013;54:7793–802.24168989 10.1167/iovs.13-13128
86. Nakamura S Shibuya M Nakashima H Hisamura R Masuda N Imagawa T Involvement of oxidative stress on corneal epithelial alterations in a blink-suppressed dry eye Investig Ophthalmol Vis Sci 2007 48 1552 8 10.1167/iovs.06-1027 17389484
Nakamura S, Shibuya M, Nakashima H, Hisamura R, Masuda N, Imagawa T, et al. Involvement of oxidative stress on corneal epithelial alterations in a blink-suppressed dry eye. Investig Ophthalmol Vis Sci. 2007;48:1552–8.17389484 10.1167/iovs.06-1027
87. Bartoloni E Ludovini V Alunno A Pistola L Bistoni O Crino L Increased levels of circulating DNA in patients with systemic autoimmune diseases: a possible marker of disease activity in Sjogren’s syndrome Lupus 2011 20 928 35 10.1177/0961203311399606 21613330
Bartoloni E, Ludovini V, Alunno A, Pistola L, Bistoni O, Crino L, et al. Increased levels of circulating DNA in patients with systemic autoimmune diseases: a possible marker of disease activity in Sjogren’s syndrome. Lupus. 2011;20:928–35.21613330 10.1177/0961203311399606
88. Vakrakou AG Boiu S Ziakas PD Xingi E Boleti H Manoussakis MN Systemic activation of NLRP3 inflammasome in patients with severe primary Sjogren’s syndrome fueled by inflammagenic DNA accumulations J Autoimmun 2018 91 23 33 10.1016/j.jaut.2018.02.010 29551295
Vakrakou AG, Boiu S, Ziakas PD, Xingi E, Boleti H, Manoussakis MN. Systemic activation of NLRP3 inflammasome in patients with severe primary Sjogren’s syndrome fueled by inflammagenic DNA accumulations. J Autoimmun. 2018;91:23–33.29551295 10.1016/j.jaut.2018.02.010
89. Archer SL Mitochondrial dynamics–mitochondrial fission and fusion in human diseases N Engl J Med 2013 369 2236 51 10.1056/NEJMra1215233 24304053
Archer SL. Mitochondrial dynamics–mitochondrial fission and fusion in human diseases. N Engl J Med. 2013;369:2236–51.24304053 10.1056/NEJMra1215233
90. Molina AJ Wikstrom JD Stiles L Las G Mohamed H Elorza A Mitochondrial networking protects beta-cells from nutrient-induced apoptosis Diabetes 2009 58 2303 15 10.2337/db07-1781 19581419
Molina AJ, Wikstrom JD, Stiles L, Las G, Mohamed H, Elorza A, et al. Mitochondrial networking protects beta-cells from nutrient-induced apoptosis. Diabetes. 2009;58:2303–15.19581419 10.2337/db07-1781
91. Liu D Gao Y Liu J Huang Y Yin J Feng Y Intercellular mitochondrial transfer as a means of tissue revitalization Signal Transduct Target Ther 2021 6 65 10.1038/s41392-020-00440-z 33589598
Liu D, Gao Y, Liu J, Huang Y, Yin J, Feng Y, et al. Intercellular mitochondrial transfer as a means of tissue revitalization. Signal Transduct Target Ther. 2021;6:65.33589598 10.1038/s41392-020-00440-z
92. Hayakawa K Esposito E Wang X Terasaki Y Liu Y Xing C Transfer of mitochondria from astrocytes to neurons after stroke Nature 2016 535 551 5 10.1038/nature18928 27466127
Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, et al. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016;535:551–5.27466127 10.1038/nature18928
93. Yip HK Dubey NK Lin KC Sung PH Chiang JY Chu YC Melatonin rescues cerebral ischemic events through upregulated tunneling nanotube-mediated mitochondrial transfer and downregulated mitochondrial oxidative stress in rat brain Biomed Pharmacother 2021 139 111593 10.1016/j.biopha.2021.111593 33865018
Yip HK, Dubey NK, Lin KC, Sung PH, Chiang JY, Chu YC, et al. Melatonin rescues cerebral ischemic events through upregulated tunneling nanotube-mediated mitochondrial transfer and downregulated mitochondrial oxidative stress in rat brain. Biomed Pharmacother. 2021;139:111593.33865018 10.1016/j.biopha.2021.111593
94. Torralba D Baixauli F Sánchez-Madrid F Mitochondria know no boundaries: mechanisms and functions of intercellular mitochondrial transfer Front Cell Dev Biol 2016 4 107 10.3389/fcell.2016.00107 27734015
Torralba D, Baixauli F, Sánchez-Madrid F. Mitochondria know no boundaries: mechanisms and functions of intercellular mitochondrial transfer. Front Cell Dev Biol. 2016;4:107.27734015 10.3389/fcell.2016.00107
95. Chinnery HR Keller KE Tunneling nanotubes and the eye: intercellular communication and implications for ocular health and disease Biomed Res Int 2020 2020 7246785 10.1155/2020/7246785 32352005
Chinnery HR, Keller KE. Tunneling nanotubes and the eye: intercellular communication and implications for ocular health and disease. Biomed Res Int. 2020;2020:7246785.32352005 10.1155/2020/7246785
96. Jiang D Xu W Peng F Sun Y Pan C Yu J Tunneling nanotubes-based intercellular mitochondrial trafficking as a novel therapeutic target in dry eye Exp Eye Res 2023 232 109497 10.1016/j.exer.2023.109497 37169281
Jiang D, Xu W, Peng F, Sun Y, Pan C, Yu J, et al. Tunneling nanotubes-based intercellular mitochondrial trafficking as a novel therapeutic target in dry eye. Exp Eye Res. 2023;232:109497.37169281 10.1016/j.exer.2023.109497
97. Danieli MG Antonelli E Piga MA Cozzi MF Allegra A Gangemi S Oxidative stress, mitochondrial dysfunction, and respiratory chain enzyme defects in inflammatory myopathies Autoimmun Rev 2023 22 103308 10.1016/j.autrev.2023.103308 36822387
Danieli MG, Antonelli E, Piga MA, Cozzi MF, Allegra A, Gangemi S. Oxidative stress, mitochondrial dysfunction, and respiratory chain enzyme defects in inflammatory myopathies. Autoimmun Rev. 2023;22:103308.36822387 10.1016/j.autrev.2023.103308
98. Martínez-Reyes I Chandel NS Mitochondrial TCA cycle metabolites control physiology and disease Nat Commun 2020 11 102 10.1038/s41467-019-13668-3 31900386
Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102.31900386 10.1038/s41467-019-13668-3
99. Ye L Jiang Y Zhang M Crosstalk between glucose metabolism, lactate production and immune response modulation Cytokine Growth Factor Rev 2022 68 81 92 10.1016/j.cytogfr.2022.11.001 36376165
Ye L, Jiang Y, Zhang M. Crosstalk between glucose metabolism, lactate production and immune response modulation. Cytokine Growth Factor Rev. 2022;68:81–92.36376165 10.1016/j.cytogfr.2022.11.001
100. Pflugfelder SC de Paiva CS The pathophysiology of dry eye disease: what we know and future directions for research Ophthalmology 2017 124 S4 s13 10.1016/j.ophtha.2017.07.010 29055361
Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124:S4–s13.29055361 10.1016/j.ophtha.2017.07.010
101. Nair AP D’Souza S Khamar P Nuijts R Sethu S Shetty R Ocular surface immune cell diversity in dry eye disease Indian J Ophthalmol 2023 71 1237 47 10.4103/IJO.IJO_2986_22 37026254
Nair AP, D’Souza S, Khamar P, Nuijts R, Sethu S, Shetty R. Ocular surface immune cell diversity in dry eye disease. Indian J Ophthalmol. 2023;71:1237–47.37026254 10.4103/IJO.IJO_2986_22
102. Perez VL Stern ME Pflugfelder SC Inflammatory basis for dry eye disease flares Exp Eye Res 2020 201 108294 10.1016/j.exer.2020.108294 33039458
Perez VL, Stern ME, Pflugfelder SC. Inflammatory basis for dry eye disease flares. Exp Eye Res. 2020;201:108294.33039458 10.1016/j.exer.2020.108294
103. Levine H Hwang J Dermer H Mehra D Feuer W Galor A Relationships between activated dendritic cells and dry eye symptoms and signs Ocul Surf 2021 21 186 92 10.1016/j.jtos.2021.06.001 34102312
Levine H, Hwang J, Dermer H, Mehra D, Feuer W, Galor A. Relationships between activated dendritic cells and dry eye symptoms and signs. Ocul Surf. 2021;21:186–92.34102312 10.1016/j.jtos.2021.06.001
104. Kelly B O’Neill LA Metabolic reprogramming in macrophages and dendritic cells in innate immunity Cell Res 2015 25 771 84 10.1038/cr.2015.68 26045163
Kelly B, O’Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25:771–84.26045163 10.1038/cr.2015.68
105. Reyes JL Vannan DT Eksteen B Avelar IJ Rodríguez T González MI Innate and adaptive cell populations driving inflammation in dry eye disease Mediators Inflamm 2018 2018 2532314 10.1155/2018/2532314 30158831
Reyes JL, Vannan DT, Eksteen B, Avelar IJ, Rodríguez T, González MI, et al. Innate and adaptive cell populations driving inflammation in dry eye disease. Mediators Inflamm. 2018;2018:2532314.30158831 10.1155/2018/2532314
106. Mashaghi A Hong J Chauhan SK Dana R Ageing and ocular surface immunity Br J Ophthalmol 2017 101 1 5 10.1136/bjophthalmol-2015-307848 27378485
Mashaghi A, Hong J, Chauhan SK, Dana R. Ageing and ocular surface immunity. Br J Ophthalmol. 2017;101:1–5.27378485 10.1136/bjophthalmol-2015-307848
107. Ogawa Y, Takeuchi T, Tsubota K. Autoimmune epithelitis and chronic inflammation in Sjögren’s syndrome-related dry eye disease. Int J Mol Sci. 2021;22:11820.
108. Faas MM de Vos P Mitochondrial function in immune cells in health and disease Biochim Biophys Acta Mol Basis Dis 2020 1866 165845 10.1016/j.bbadis.2020.165845 32473386
Faas MM, de Vos P. Mitochondrial function in immune cells in health and disease. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165845.32473386 10.1016/j.bbadis.2020.165845
109. Xu Y Chiang YH Ho PC Vannini N Mitochondria dictate function and fate of HSCs and T cells Cancer Immunol Res 2023 11 1303 13 10.1158/2326-6066.CIR-22-0685 37789763
Xu Y, Chiang YH, Ho PC, Vannini N. Mitochondria dictate function and fate of HSCs and T cells. Cancer Immunol Res. 2023;11:1303–13.37789763 10.1158/2326-6066.CIR-22-0685
110. Liu X Peng G Mitochondria orchestrate T cell fate and function Nat Immunol 2021 22 276 8 10.1038/s41590-020-00861-6 33495653
Liu X, Peng G. Mitochondria orchestrate T cell fate and function. Nat Immunol. 2021;22:276–8.33495653 10.1038/s41590-020-00861-6
111. Wenes M Jaccard A Wyss T Maldonado-Pérez N Teoh ST Lepez A The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function Cell Metab 2022 34 731 46.e9 10.1016/j.cmet.2022.03.013 35452600
Wenes M, Jaccard A, Wyss T, Maldonado-Pérez N, Teoh ST, Lepez A, et al. The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function. Cell Metab. 2022;34:731–46.e9.35452600 10.1016/j.cmet.2022.03.013
112. Courtin R Pereira B Naughton G Chamoux A Chiambaretta F Lanhers C Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis BMJ Open 2016 6 e009675 10.1136/bmjopen-2015-009675 26769784
Courtin R, Pereira B, Naughton G, Chamoux A, Chiambaretta F, Lanhers C, et al. Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis. BMJ Open. 2016;6:e009675.26769784 10.1136/bmjopen-2015-009675
113. Pimputkar S, Speck JS, Denbaars SP, Nakamura SJNP. Prospects for LED lighting. Nature Photonics. 2009;3:180–2.
114. Renard G Leid J [The dangers of blue light: True story!] J Fr Ophtalmol 2016 39 483 8 10.1016/j.jfo.2016.02.003 27039979
Renard G, Leid J. [The dangers of blue light: True story!]. J Fr Ophtalmol. 2016;39:483–8.27039979 10.1016/j.jfo.2016.02.003
115. Guo KX Huang C Wang W Zhang P Li Y Liu ZY Oxidative stress and mitochondrial dysfunction of retinal ganglion cells injury exposures in long-term blue light Int J Ophthalmol 2020 13 1854 63 10.18240/ijo.2020.12.03 33344182
Guo KX, Huang C, Wang W, Zhang P, Li Y, Liu ZY, et al. Oxidative stress and mitochondrial dysfunction of retinal ganglion cells injury exposures in long-term blue light. Int J Ophthalmol. 2020;13:1854–63.33344182 10.18240/ijo.2020.12.03
116. Osborne NN Nunez-Alvarez C Del Olmo-Aguado S Merrayo-Lloves J Visual light effects on mitochondria: The potential implications in relation to glaucoma Mitochondrion 2017 36 29 35 10.1016/j.mito.2016.11.009 27890822
Osborne NN, Nunez-Alvarez C, Del Olmo-Aguado S, Merrayo-Lloves J. Visual light effects on mitochondria: The potential implications in relation to glaucoma. Mitochondrion. 2017;36:29–35.27890822 10.1016/j.mito.2016.11.009
117. Nunez-Alvarez C Osborne NN Enhancement of corneal epithelium cell survival, proliferation and migration by red light: Relevance to corneal wound healing Exp Eye Res 2019 180 231 41 10.1016/j.exer.2019.01.003 30611737
Nunez-Alvarez C, Osborne NN. Enhancement of corneal epithelium cell survival, proliferation and migration by red light: Relevance to corneal wound healing. Exp Eye Res. 2019;180:231–41.30611737 10.1016/j.exer.2019.01.003
118. Lee HS Cui L Li Y Choi JS Choi JH Li Z Influence of light emitting diode-derived blue light overexposure on mouse ocular surface PLoS ONE 2016 11 e0161041 10.1371/journal.pone.0161041 27517861
Lee HS, Cui L, Li Y, Choi JS, Choi JH, Li Z, et al. Influence of light emitting diode-derived blue light overexposure on mouse ocular surface. PLoS ONE. 2016;11:e0161041.27517861 10.1371/journal.pone.0161041
119. Marek V Melik-Parsadaniantz S Villette T Montoya F Baudouin C Brignole-Baudouin F Blue light phototoxicity toward human corneal and conjunctival epithelial cells in basal and hyperosmolar conditions Free Radic Biol Med 2018 126 27 40 10.1016/j.freeradbiomed.2018.07.012 30040995
Marek V, Melik-Parsadaniantz S, Villette T, Montoya F, Baudouin C, Brignole-Baudouin F, et al. Blue light phototoxicity toward human corneal and conjunctival epithelial cells in basal and hyperosmolar conditions. Free Radic Biol Med. 2018;126:27–40.30040995 10.1016/j.freeradbiomed.2018.07.012
120. Niwano Y Iwasawa A Tsubota K Ayaki M Negishi K Protective effects of blue light-blocking shades on phototoxicity in human ocular surface cells BMJ Open Ophthalmol 2019 4 e000217 10.1136/bmjophth-2018-000217 31245609
Niwano Y, Iwasawa A, Tsubota K, Ayaki M, Negishi K. Protective effects of blue light-blocking shades on phototoxicity in human ocular surface cells. BMJ Open Ophthalmol. 2019;4:e000217.31245609 10.1136/bmjophth-2018-000217
121. Ouyang X Yang J Hong Z Wu Y Xie Y Wang G Mechanisms of blue light-induced eye hazard and protective measures: a review Biomed Pharmacother 2020 130 110577 10.1016/j.biopha.2020.110577 32763817
Ouyang X, Yang J, Hong Z, Wu Y, Xie Y, Wang G. Mechanisms of blue light-induced eye hazard and protective measures: a review. Biomed Pharmacother. 2020;130:110577.32763817 10.1016/j.biopha.2020.110577
122. Rosenfield M Li RT Kirsch NT A double-blind test of blue-blocking filters on symptoms of digital eye strain Work 2020 65 343 8 10.3233/WOR-203086 32007978
Rosenfield M, Li RT, Kirsch NT. A double-blind test of blue-blocking filters on symptoms of digital eye strain. Work. 2020;65:343–8.32007978 10.3233/WOR-203086
123. Palavets T Rosenfield M Blue-blocking filters and digital eyestrain Optom Vis Sci 2019 96 48 54 10.1097/OPX.0000000000001318 30570598
Palavets T, Rosenfield M. Blue-blocking filters and digital eyestrain. Optom Vis Sci. 2019;96:48–54.30570598 10.1097/OPX.0000000000001318
124. Singh S Downie LE Anderson AJ Do blue-blocking lenses reduce eye strain from extended screen time? A double-masked randomized controlled trial Am J Ophthalmol 2021 226 243 51 10.1016/j.ajo.2021.02.010 33587901
Singh S, Downie LE, Anderson AJ. Do blue-blocking lenses reduce eye strain from extended screen time? A double-masked randomized controlled trial. Am J Ophthalmol. 2021;226:243–51.33587901 10.1016/j.ajo.2021.02.010
125. Fox RI Sjogren’s syndrome Lancet 2005 366 321 31 10.1016/S0140-6736(05)66990-5 16039337
Fox RI. Sjogren’s syndrome. Lancet. 2005;366:321–31.16039337 10.1016/S0140-6736(05)66990-5
126. Webb J Whaley K MacSween RN Nuki G Dick WC Buchanan WW Liver disease in rheumatoid arthritis and Sjogren’s syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction Ann Rheum Dis 1975 34 70 81 10.1136/ard.34.1.70 1092275
Webb J, Whaley K, MacSween RN, Nuki G, Dick WC, Buchanan WW. Liver disease in rheumatoid arthritis and Sjogren’s syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction. Ann Rheum Dis. 1975;34:70–81.1092275 10.1136/ard.34.1.70
127. Xu Y Shen J Ran Z Emerging views of mitophagy in immunity and autoimmune diseases Autophagy 2020 16 3 17 10.1080/15548627.2019.1603547 30951392
Xu Y, Shen J, Ran Z. Emerging views of mitophagy in immunity and autoimmune diseases. Autophagy. 2020;16:3–17.30951392 10.1080/15548627.2019.1603547
128. Escames G Lopez LC Garcia JA Garcia-Corzo L Ortiz F Acuna-Castroviejo D Mitochondrial DNA and inflammatory diseases Hum Genet 2012 131 161 73 10.1007/s00439-011-1057-y 21735170
Escames G, Lopez LC, Garcia JA, Garcia-Corzo L, Ortiz F, Acuna-Castroviejo D. Mitochondrial DNA and inflammatory diseases. Hum Genet. 2012;131:161–73.21735170 10.1007/s00439-011-1057-y
129. Pagano G Castello G Pallardo FV Sjogren’s syndrome-associated oxidative stress and mitochondrial dysfunction: prospects for chemoprevention trials Free Radic Res 2013 47 71 3 10.3109/10715762.2012.748904 23153390
Pagano G, Castello G, Pallardo FV. Sjogren’s syndrome-associated oxidative stress and mitochondrial dysfunction: prospects for chemoprevention trials. Free Radic Res. 2013;47:71–3.23153390 10.3109/10715762.2012.748904
130. Kim J, Kim YS, Park SH. Metformin as a treatment strategy for Sjogren’s Syndrome. Int J Mol Sci. 2021;22:7231.
131. Srivastava G Kumar RB Once-weekly semaglutide in adults with overweight or obesity N Engl J Med 2021 385 e4 34192449
Srivastava G, Kumar RB. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;385:e4.34192449
132. Mohammed MS Sendra S Lloret J Bosch I Systems and WBANs for controlling obesity J Health Eng 2018 2018 1564748 10.1155/2018/1564748
Mohammed MS, Sendra S, Lloret J, Bosch I. Systems and WBANs for controlling obesity. J Health Eng. 2018;2018:1564748.10.1155/2018/1564748
133. Bluher M Obesity: global epidemiology and pathogenesis Nat Rev Endocrinol 2019 15 288 98 10.1038/s41574-019-0176-8 30814686
Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288–98.30814686 10.1038/s41574-019-0176-8
134. Piche ME Tchernof A Despres JP Obesity phenotypes, diabetes, and cardiovascular diseases Circ Res 2020 126 1477 500 10.1161/CIRCRESAHA.120.316101 32437302
Piche ME, Tchernof A, Despres JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126:1477–500.32437302 10.1161/CIRCRESAHA.120.316101
135. Seravalle G Grassi G Obesity and hypertension Pharmacol Res 2017 122 1 7 10.1016/j.phrs.2017.05.013 28532816
Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1–7.28532816 10.1016/j.phrs.2017.05.013
136. Mana MD Hussey AM Tzouanas CN Imada S Barrera Millan Y Bahceci D High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity Cell Rep 2021 35 109212 10.1016/j.celrep.2021.109212 34107251
Mana MD, Hussey AM, Tzouanas CN, Imada S, Barrera Millan Y, Bahceci D, et al. High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity. Cell Rep. 2021;35:109212.34107251 10.1016/j.celrep.2021.109212
137. He X Zhao Z Wang S Kang J Zhang M Bu J High-fat diet-induced functional and pathologic changes in lacrimal gland Am J Pathol 2020 190 2387 402 10.1016/j.ajpath.2020.09.002 32919976
He X, Zhao Z, Wang S, Kang J, Zhang M, Bu J, et al. High-fat diet-induced functional and pathologic changes in lacrimal gland. Am J Pathol. 2020;190:2387–402.32919976 10.1016/j.ajpath.2020.09.002
138. Bu J Wu Y Cai X Jiang N Jeyalatha MV Yu J Hyperlipidemia induces meibomian gland dysfunction Ocul Surf 2019 17 777 86 10.1016/j.jtos.2019.06.002 31201956
Bu J, Wu Y, Cai X, Jiang N, Jeyalatha MV, Yu J, et al. Hyperlipidemia induces meibomian gland dysfunction. Ocul Surf. 2019;17:777–86.31201956 10.1016/j.jtos.2019.06.002
139. Wu Y Wu J Bu J Tang L Yang Y Ouyang W High-fat diet induces dry eye-like ocular surface damages in murine Ocul Surf 2020 18 267 76 10.1016/j.jtos.2020.02.009 32120007
Wu Y, Wu J, Bu J, Tang L, Yang Y, Ouyang W, et al. High-fat diet induces dry eye-like ocular surface damages in murine. Ocul Surf. 2020;18:267–76.32120007 10.1016/j.jtos.2020.02.009
140. Crispino M, Trinchese G, Penna E, Cimmino F, Catapano A, Villano I, et al. Interplay between peripheral and central inflammation in obesity-promoted disorders: the impact on synaptic mitochondrial functions. Int J Mol Sci. 2020;21:5964–86.
141. Zalewska A, Maciejczyk M, Szulimowska J, Imierska M, Blachnio-Zabielska A. High-fat diet affects ceramide content, disturbs mitochondrial redox balance, and induces apoptosis in the submandibular glands of mice. Biomolecules. 2019;9.
142. Putti R Migliaccio V Sica R Lionetti L Skeletal muscle mitochondrial bioenergetics and morphology in high fat diet induced obesity and insulin resistance: focus on dietary fat source Front Physiol 2015 6 426 26834644
Putti R, Migliaccio V, Sica R, Lionetti L. Skeletal muscle mitochondrial bioenergetics and morphology in high fat diet induced obesity and insulin resistance: focus on dietary fat source. Front Physiol. 2015;6:426.26834644
143. Liu R Jin P Yu L Wang Y Han L Shi T Impaired mitochondrial dynamics and bioenergetics in diabetic skeletal muscle PloS one 2014 9 e92810 10.1371/journal.pone.0092810 24658162
Liu R, Jin P, Yu L, Wang Y, Han L, Shi T, et al. Impaired mitochondrial dynamics and bioenergetics in diabetic skeletal muscle. PloS one. 2014;9:e92810.24658162 10.1371/journal.pone.0092810
144. Boyko E IDF plans dynamic 2019 congress Diab Res Clin Pract 2019 150 342 3 10.1016/j.diabres.2019.04.027
Boyko E. IDF plans dynamic 2019 congress. Diab Res Clin Pract. 2019;150:342–3.10.1016/j.diabres.2019.04.027
145. Ljubimov AV Diabetic complications in the cornea Vis Res 2017 139 138 52 10.1016/j.visres.2017.03.002 28404521
Ljubimov AV. Diabetic complications in the cornea. Vis Res. 2017;139:138–52.28404521 10.1016/j.visres.2017.03.002
146. Manaviat MR Rashidi M Afkhami-Ardekani M Shoja MR Prevalence of dry eye syndrome and diabetic retinopathy in type 2 diabetic patients BMC Ophthalmol 2008 8 10 10.1186/1471-2415-8-10 18513455
Manaviat MR, Rashidi M, Afkhami-Ardekani M, Shoja MR. Prevalence of dry eye syndrome and diabetic retinopathy in type 2 diabetic patients. BMC Ophthalmol. 2008;8:10.18513455 10.1186/1471-2415-8-10
147. Rovira-Llopis S Banuls C Diaz-Morales N Hernandez-Mijares A Rocha M Victor VM Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications Redox Biol 2017 11 637 45 10.1016/j.redox.2017.01.013 28131082
Rovira-Llopis S, Banuls C, Diaz-Morales N, Hernandez-Mijares A, Rocha M, Victor VM. Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. Redox Biol. 2017;11:637–45.28131082 10.1016/j.redox.2017.01.013
148. Belosludtsev KN, Belosludtseva NV, Dubinin MV. Diabetes mellitus, mitochondrial dysfunction and Ca(2+)-dependent permeability transition pore. Int J Mol Sci. 2020;21:6559–91.
149. Wang CH Wei YH Role of mitochondrial dysfunction and dysregulation of Ca(2+) homeostasis in the pathophysiology of insulin resistance and type 2 diabetes J Biomed Sci 2017 24 70 10.1186/s12929-017-0375-3 28882140
Wang CH, Wei YH. Role of mitochondrial dysfunction and dysregulation of Ca(2+) homeostasis in the pathophysiology of insulin resistance and type 2 diabetes. J Biomed Sci. 2017;24:70.28882140 10.1186/s12929-017-0375-3
150. Qu M Wan L Dong M Wang Y Xie L Zhou Q Hyperglycemia-induced severe mitochondrial bioenergetic deficit of lacrimal gland contributes to the early onset of dry eye in diabetic mice Free Radic Biol Med 2021 166 313 23 10.1016/j.freeradbiomed.2021.02.036 33705960
Qu M, Wan L, Dong M, Wang Y, Xie L, Zhou Q. Hyperglycemia-induced severe mitochondrial bioenergetic deficit of lacrimal gland contributes to the early onset of dry eye in diabetic mice. Free Radic Biol Med. 2021;166:313–23.33705960 10.1016/j.freeradbiomed.2021.02.036
151. McClellan AJ Volpe EA Zhang X Darlington GJ Li DQ Pflugfelder SC Ocular surface disease and dacryoadenitis in aging C57BL/6 mice Am J Pathol 2014 184 631 43 10.1016/j.ajpath.2013.11.019 24389165
McClellan AJ, Volpe EA, Zhang X, Darlington GJ, Li DQ, Pflugfelder SC, et al. Ocular surface disease and dacryoadenitis in aging C57BL/6 mice. Am J Pathol. 2014;184:631–43.24389165 10.1016/j.ajpath.2013.11.019
152. Parfitt GJ Xie Y Geyfman M Brown DJ Jester JV Absence of ductal hyper-keratinization in mouse age-related meibomian gland dysfunction (ARMGD) Aging 2013 5 825 34 10.18632/aging.100615 24259272
Parfitt GJ, Xie Y, Geyfman M, Brown DJ, Jester JV. Absence of ductal hyper-keratinization in mouse age-related meibomian gland dysfunction (ARMGD). Aging. 2013;5:825–34.24259272 10.18632/aging.100615
153. de Paiva CS Effects of aging in dry eye Int Ophthalmol Clin 2017 57 47 64 10.1097/IIO.0000000000000170 28282314
de Paiva CS. Effects of aging in dry eye. Int Ophthalmol Clin. 2017;57:47–64.28282314 10.1097/IIO.0000000000000170
154. Kojima T Wakamatsu TH Dogru M Ogawa Y Igarashi A Ibrahim OM Age-related dysfunction of the lacrimal gland and oxidative stress: evidence from the Cu,Zn-superoxide dismutase-1 (Sod1) knockout mice Am J Pathol 2012 180 1879 96 10.1016/j.ajpath.2012.01.019 22440255
Kojima T, Wakamatsu TH, Dogru M, Ogawa Y, Igarashi A, Ibrahim OM, et al. Age-related dysfunction of the lacrimal gland and oxidative stress: evidence from the Cu,Zn-superoxide dismutase-1 (Sod1) knockout mice. Am J Pathol. 2012;180:1879–96.22440255 10.1016/j.ajpath.2012.01.019
155. Shimokawa T Yoshida M Fukuta T Tanaka T Inagi T Kogure K Efficacy of high-affinity liposomal astaxanthin on up-regulation of age-related markers induced by oxidative stress in human corneal epithelial cells J Clin Biochem Nutr 2019 64 27 35 10.3164/jcbn.18-27 30705509
Shimokawa T, Yoshida M, Fukuta T, Tanaka T, Inagi T, Kogure K. Efficacy of high-affinity liposomal astaxanthin on up-regulation of age-related markers induced by oxidative stress in human corneal epithelial cells. J Clin Biochem Nutr. 2019;64:27–35.30705509 10.3164/jcbn.18-27
156. Genova ML Lenaz G The interplay between respiratory supercomplexes and ROS in aging Antioxid Redox Signal 2015 23 208 38 10.1089/ars.2014.6214 25711676
Genova ML, Lenaz G. The interplay between respiratory supercomplexes and ROS in aging. Antioxid Redox Signal. 2015;23:208–38.25711676 10.1089/ars.2014.6214
157. Ouyang W Wu Y Lin X Wang S Yang Y Tang L Role of CD4+ T helper cells in the development of BAC-induced dry eye syndrome in mice Investig Ophthalmol Vis Sci 2021 62 25 10.1167/iovs.62.1.25
Ouyang W, Wu Y, Lin X, Wang S, Yang Y, Tang L, et al. Role of CD4+ T helper cells in the development of BAC-induced dry eye syndrome in mice. Investig Ophthalmol Vis Sci. 2021;62:25.10.1167/iovs.62.1.25
158. Datta S Baudouin C Brignole-Baudouin F Denoyer A Cortopassi GA The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells Investig Ophthalmol Vis Sci 2017 58 2406 12 10.1167/iovs.16-20903 28444329
Datta S, Baudouin C, Brignole-Baudouin F, Denoyer A, Cortopassi GA. The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells. Investig Ophthalmol Vis Sci. 2017;58:2406–12.28444329 10.1167/iovs.16-20903
159. Debbasch C De La Salle SB Brignole F Rat P Warnet JM Baudouin C Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells Invest Ophthalmol Vis Sci 2002 43 3409 15 12407150
Debbasch C, De La Salle SB, Brignole F, Rat P, Warnet JM, Baudouin C. Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells. Invest Ophthalmol Vis Sci. 2002;43:3409–15.12407150
160. Na YJ, Choi KJ, Jung WH, Park SB, Kang S, Ahn JH, et al. A novel selective 11beta-HSD1 inhibitor, (E)-4-(2-(6-(2,6-dichloro-4-(Trifluoromethyl)Phenyl)-4-Methyl-1,1-Dioxido-1,2,6-T hiadiazinan-2-yl)acetamido)adamantan-1-carboxamide (KR-67607), prevents BAC-induced dry eye syndrome. Int J Mol Sci. 2020;21:3729.
161. Zhang W Li W Zhang C Zhu C Yi X Zhou Y Effects of vitamin A on expressions of apoptosis genes Bax and Bcl-2 in epithelial cells of corneal tissues induced by benzalkonium chloride in mice with dry eye Med Sci Monit 2019 25 4583 9 10.12659/MSM.913478 31257361
Zhang W, Li W, Zhang C, Zhu C, Yi X, Zhou Y, et al. Effects of vitamin A on expressions of apoptosis genes Bax and Bcl-2 in epithelial cells of corneal tissues induced by benzalkonium chloride in mice with dry eye. Med Sci Monit. 2019;25:4583–9.31257361 10.12659/MSM.913478
162. Ma Q Role of nrf2 in oxidative stress and toxicity Annu Rev Pharmacol Toxicol 2013 53 401 26 10.1146/annurev-pharmtox-011112-140320 23294312
Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–26.23294312 10.1146/annurev-pharmtox-011112-140320
163. Li Y Liu H Zeng W Wei J Edaravone protects against hyperosmolarity-induced oxidative stress and apoptosis in primary human corneal epithelial cells PLoS ONE 2017 12 e0174437 10.1371/journal.pone.0174437 28346481
Li Y, Liu H, Zeng W, Wei J. Edaravone protects against hyperosmolarity-induced oxidative stress and apoptosis in primary human corneal epithelial cells. PLoS ONE. 2017;12:e0174437.28346481 10.1371/journal.pone.0174437
164. Zhang Y An Y He X Zhang D He W Esculetin protects human corneal epithelial cells from oxidative stress through Nrf-2 signaling pathway Exp Eye Res 2021 202 108360 10.1016/j.exer.2020.108360 33220236
Zhang Y, An Y, He X, Zhang D, He W. Esculetin protects human corneal epithelial cells from oxidative stress through Nrf-2 signaling pathway. Exp Eye Res. 2021;202:108360.33220236 10.1016/j.exer.2020.108360
165. Dai Y Zhang J Xiang J Li Y Wu D Xu J Calcitriol inhibits ROS-NLRP3-IL-1beta signaling axis via activation of Nrf2-antioxidant signaling in hyperosmotic stress stimulated human corneal epithelial cells Redox Biol 2019 21 101093 10.1016/j.redox.2018.101093 30611121
Dai Y, Zhang J, Xiang J, Li Y, Wu D, Xu J. Calcitriol inhibits ROS-NLRP3-IL-1beta signaling axis via activation of Nrf2-antioxidant signaling in hyperosmotic stress stimulated human corneal epithelial cells. Redox Biol. 2019;21:101093.30611121 10.1016/j.redox.2018.101093
166. Almeida Moreira Leal LK Lima LA Alexandre de Aquino PE Costa de Sousa JA Jatai Gadelha CV Felicio Calou IB Vitamin D (VD3) antioxidative and anti-inflammatory activities: Peripheral and central effects Eur J Pharmacol 2020 879 173099 10.1016/j.ejphar.2020.173099 32360837
Almeida Moreira Leal LK, Lima LA, Alexandre de Aquino PE, Costa de Sousa JA, Jatai Gadelha CV, Felicio Calou IB, et al. Vitamin D (VD3) antioxidative and anti-inflammatory activities: Peripheral and central effects. Eur J Pharmacol. 2020;879:173099.32360837 10.1016/j.ejphar.2020.173099
167. Higgins MR, Izadi A, Kaviani M. Antioxidants and exercise performance: with a focus on vitamin E and C supplementation. Int J Environ Res Public Health. 2020;17:8452.
168. Shetty R Subramani M Murugeswari P Anandula VR Matalia H Jayadev C Resveratrol rescues human corneal epithelial cells cultured in hyperosmolar conditions: potential for dry eye disease treatment Cornea 2020 39 1520 32 10.1097/ICO.0000000000002495 32947396
Shetty R, Subramani M, Murugeswari P, Anandula VR, Matalia H, Jayadev C, et al. Resveratrol rescues human corneal epithelial cells cultured in hyperosmolar conditions: potential for dry eye disease treatment. Cornea. 2020;39:1520–32.32947396 10.1097/ICO.0000000000002495
169. Saprunova VB, Lelekova MA, Kolosova NG, Bakeeva LE. SkQ1 slows development of age-dependent destructive processes in retina and vascular layer of eyes of wistar and OXYS rats. Biochemistry. 2012;77:648–58.
170. Neroev VV, Archipova MM, Bakeeva LE, Fursova A, Grigorian EN, Grishanova AY, et al. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 4. Age-related eye disease. SkQ1 returns vision to blind animals. Biochemistry. 2008;73:1317–28.
171. Zernii EY Gancharova OS Baksheeva VE Golovastova MO Kabanova EI Savchenko MS Mitochondria-targeted antioxidant SkQ1 prevents anesthesia-induced dry eye syndrome Oxid Med Cell Longev 2017 2017 9281519 10.1155/2017/9281519 29158874
Zernii EY, Gancharova OS, Baksheeva VE, Golovastova MO, Kabanova EI, Savchenko MS, et al. Mitochondria-targeted antioxidant SkQ1 prevents anesthesia-induced dry eye syndrome. Oxid Med Cell Longev. 2017;2017:9281519.29158874 10.1155/2017/9281519
172. Bakeeva LE Eldarov CM Vangely IM Kolosova NG Vays VB Mitochondria-targeted antioxidant SkQ1 reduces age-related alterations in the ultrastructure of the lacrimal gland Oncotarget 2016 7 80208 22 10.18632/oncotarget.13303 27852065
Bakeeva LE, Eldarov CM, Vangely IM, Kolosova NG, Vays VB. Mitochondria-targeted antioxidant SkQ1 reduces age-related alterations in the ultrastructure of the lacrimal gland. Oncotarget. 2016;7:80208–22.27852065 10.18632/oncotarget.13303
173. Huang B Zhang N Qiu X Zeng R Wang S Hua M Mitochondria-targeted SkQ1 nanoparticles for dry eye disease: Inhibiting NLRP3 inflammasome activation by preventing mitochondrial DNA oxidation J Control Release 2024 365 1 15 10.1016/j.jconrel.2023.11.021 37972763
Huang B, Zhang N, Qiu X, Zeng R, Wang S, Hua M, et al. Mitochondria-targeted SkQ1 nanoparticles for dry eye disease: Inhibiting NLRP3 inflammasome activation by preventing mitochondrial DNA oxidation. J Control Release. 2024;365:1–15.37972763 10.1016/j.jconrel.2023.11.021
174. Petrov A Perekhvatova N Skulachev M Stein L Ousler G SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model Adv Ther 2016 33 96 115 10.1007/s12325-015-0274-5 26733410
Petrov A, Perekhvatova N, Skulachev M, Stein L, Ousler G. SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model. Adv Ther. 2016;33:96–115.26733410 10.1007/s12325-015-0274-5
175. Hardeland R. Aging, melatonin, and the pro- and anti-inflammatory networks. Int J Mol Sci. 2019;20.
176. Martinez-Aguila A, Martin-Gil A, Carpena-Torres C, Pastrana C, Carracedo G. Influence of circadian rhythm in the eye: significance of melatonin in glaucoma. Biomolecules. 2021;11.
177. Yi C Pan X Yan H Guo M Pierpaoli W Effects of melatonin in age-related macular degeneration Ann N Y Acad Sci 2005 1057 384 92 10.1196/annals.1356.029 16399908
Yi C, Pan X, Yan H, Guo M, Pierpaoli W. Effects of melatonin in age-related macular degeneration. Ann N Y Acad Sci. 2005;1057:384–92.16399908 10.1196/annals.1356.029
178. Wang B Zuo X Peng L Wang X Zeng H Zhong J Melatonin ameliorates oxidative stress-mediated injuries through induction of HO-1 and restores autophagic flux in dry eye Exp Eye Res 2021 205 108491 10.1016/j.exer.2021.108491 33587908
Wang B, Zuo X, Peng L, Wang X, Zeng H, Zhong J, et al. Melatonin ameliorates oxidative stress-mediated injuries through induction of HO-1 and restores autophagic flux in dry eye. Exp Eye Res. 2021;205:108491.33587908 10.1016/j.exer.2021.108491
179. Hoyle CH Peral A Pintor J Melatonin potentiates tear secretion induced by diadenosine tetraphosphate in the rabbit Eur J Pharmacol 2006 552 159 61 10.1016/j.ejphar.2006.09.012 17056033
Hoyle CH, Peral A, Pintor J. Melatonin potentiates tear secretion induced by diadenosine tetraphosphate in the rabbit. Eur J Pharmacol. 2006;552:159–61.17056033 10.1016/j.ejphar.2006.09.012
180. Navarro Gil FJ Huete-Toral F Crooke A Dominguez Godinez CO Carracedo G Pintor J Effect of melatonin and its analogs on tear secretion J Pharmacol Exp Ther 2019 371 186 90 10.1124/jpet.119.259192 31371479
Navarro Gil FJ, Huete-Toral F, Crooke A, Dominguez Godinez CO, Carracedo G, Pintor J. Effect of melatonin and its analogs on tear secretion. J Pharmacol Exp Ther. 2019;371:186–90.31371479 10.1124/jpet.119.259192
181. Sztretye M Dienes B Gonczi M Czirjak T Csernoch L Dux L Astaxanthin: a potential mitochondrial-targeted antioxidant treatment in diseases and with aging Oxid Med Cell Longev 2019 2019 3849692 10.1155/2019/3849692 31814873
Sztretye M, Dienes B, Gonczi M, Czirjak T, Csernoch L, Dux L, et al. Astaxanthin: a potential mitochondrial-targeted antioxidant treatment in diseases and with aging. Oxid Med Cell Longev. 2019;2019:3849692.31814873 10.1155/2019/3849692
182. Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential Alter Med Rev 2011 16 355 64
Kidd P. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alter Med Rev. 2011;16:355–64.
183. Shimokawa T Fukuta T Inagi T Kogure K Protective effect of high-affinity liposomes encapsulating astaxanthin against corneal disorder in the in vivo rat dry eye disease model J Clin Biochem Nutr 2020 66 224 32 10.3164/jcbn.19-102 32523249
Shimokawa T, Fukuta T, Inagi T, Kogure K. Protective effect of high-affinity liposomes encapsulating astaxanthin against corneal disorder in the in vivo rat dry eye disease model. J Clin Biochem Nutr. 2020;66:224–32.32523249 10.3164/jcbn.19-102
184. Lee HS Choi JH Cui L Li Y Yang JM Yun JJ Anti-inflammatory and antioxidative effects of Camellia japonica on human corneal epithelial cells and experimental dry eye: in vivo and in vitro study Investig Ophthalmol Vis Sci 2017 58 1196 207 10.1167/iovs.16-20634 28245300
Lee HS, Choi JH, Cui L, Li Y, Yang JM, Yun JJ, et al. Anti-inflammatory and antioxidative effects of Camellia japonica on human corneal epithelial cells and experimental dry eye: in vivo and in vitro study. Investig Ophthalmol Vis Sci. 2017;58:1196–207.28245300 10.1167/iovs.16-20634
185. Bucolo C Fidilio A Platania CBM Geraci F Lazzara F Drago F Antioxidant and osmoprotecting activity of taurine in dry eye models J Ocul Pharmacol Ther 2018 34 188 94 10.1089/jop.2017.0008 28771380
Bucolo C, Fidilio A, Platania CBM, Geraci F, Lazzara F, Drago F. Antioxidant and osmoprotecting activity of taurine in dry eye models. J Ocul Pharmacol Ther. 2018;34:188–94.28771380 10.1089/jop.2017.0008
186. Cui L Lee HS Li Y Choi JH Yun JJ Jung JE Experimental and clinical applications of Chamaecyparis obtusa extracts in dry eye disease Oxid Med Cell Longev 2017 2017 4523673 10.1155/2017/4523673 29441148
Cui L, Lee HS, Li Y, Choi JH, Yun JJ, Jung JE, et al. Experimental and clinical applications of Chamaecyparis obtusa extracts in dry eye disease. Oxid Med Cell Longev. 2017;2017:4523673.29441148 10.1155/2017/4523673
187. Liu H Gambino F Jr Algenio C Bouchard C Qiao L Bu P Zidovudine protects hyperosmolarity-stressed human corneal epithelial cells via antioxidant pathway Biochem Biophys Res Commun 2018 499 177 81 10.1016/j.bbrc.2018.03.112 29555477
Liu H, Gambino F Jr, Algenio C, Bouchard C, Qiao L, Bu P, et al. Zidovudine protects hyperosmolarity-stressed human corneal epithelial cells via antioxidant pathway. Biochem Biophys Res Commun. 2018;499:177–81.29555477 10.1016/j.bbrc.2018.03.112
188. Bales CW Kraus WE Caloric restriction: implications for human cardiometabolic health J Cardiopulm Rehabil Prev 2013 33 201 8 10.1097/HCR.0b013e318295019e 23748374
Bales CW, Kraus WE. Caloric restriction: implications for human cardiometabolic health. J Cardiopulm Rehabil Prev. 2013;33:201–8.23748374 10.1097/HCR.0b013e318295019e
189. Most J Tosti V Redman LM Fontana L Calorie restriction in humans: an update Ageing Res Rev 2017 39 36 45 10.1016/j.arr.2016.08.005 27544442
Most J, Tosti V, Redman LM, Fontana L. Calorie restriction in humans: an update. Ageing Res Rev. 2017;39:36–45.27544442 10.1016/j.arr.2016.08.005
190. Magkos F Hjorth MF Astrup A Diet and exercise in the prevention and treatment of type 2 diabetes mellitus Nat Rev Endocrinol 2020 16 545 55 10.1038/s41574-020-0381-5 32690918
Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16:545–55.32690918 10.1038/s41574-020-0381-5
191. Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017;9:eaai8700.
192. Longo VD Fontana L Calorie restriction and cancer prevention: metabolic and molecular mechanisms Trends Pharmacol Sci 2010 31 89 98 10.1016/j.tips.2009.11.004 20097433
Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci. 2010;31:89–98.20097433 10.1016/j.tips.2009.11.004
193. Trepanowski JF Kroeger CM Barnosky A Klempel MC Bhutani S Hoddy KK Effect of alternate-day fasting on weight loss, weight maintenance, and cardioprotection among metabolically healthy obese adults: a randomized clinical trial JAMA Intern Med 2017 177 930 8 10.1001/jamainternmed.2017.0936 28459931
Trepanowski JF, Kroeger CM, Barnosky A, Klempel MC, Bhutani S, Hoddy KK, et al. Effect of alternate-day fasting on weight loss, weight maintenance, and cardioprotection among metabolically healthy obese adults: a randomized clinical trial. JAMA Intern Med. 2017;177:930–8.28459931 10.1001/jamainternmed.2017.0936
194. Kraus WE Bhapkar M Huffman KM Pieper CF Krupa Das S Redman LM 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial Lancet Diab Endocrinol 2019 7 673 83 10.1016/S2213-8587(19)30151-2
Kraus WE, Bhapkar M, Huffman KM, Pieper CF, Krupa Das S, Redman LM, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. Lancet Diab Endocrinol. 2019;7:673–83.10.1016/S2213-8587(19)30151-2
195. Johnson JB Summer W Cutler RG Martin B Hyun DH Dixit VD Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma Free Radic Biol Med 2007 42 665 74 10.1016/j.freeradbiomed.2006.12.005 17291990
Johnson JB, Summer W, Cutler RG, Martin B, Hyun DH, Dixit VD, et al. Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic Biol Med. 2007;42:665–74.17291990 10.1016/j.freeradbiomed.2006.12.005
196. Fontana L, Ghezzi L, Cross AH, Piccio L. Effects of dietary restriction on neuroinflammation in neurodegenerative diseases. J Exp Med. 2021;218.
197. Parveen S Impact of calorie restriction and intermittent fasting on periodontal health Periodontol 2000 2021 87 315 24 10.1111/prd.12400 34463980
Parveen S. Impact of calorie restriction and intermittent fasting on periodontal health. Periodontol 2000. 2021;87:315–24.34463980 10.1111/prd.12400
198. Michalsen A Li C Fasting therapy for treating and preventing disease - current state of evidence Forsch Komplementmed 2013 20 444 53 24434759
Michalsen A, Li C. Fasting therapy for treating and preventing disease - current state of evidence. Forsch Komplementmed. 2013;20:444–53.24434759
199. Kawashima M Ozawa Y Shinmura K Inaba T Nakamura S Kawakita T Calorie restriction (CR) and CR mimetics for the prevention and treatment of age-related eye disorders Exp Gerontol 2013 48 1096 100 10.1016/j.exger.2013.04.002 23588119
Kawashima M, Ozawa Y, Shinmura K, Inaba T, Nakamura S, Kawakita T, et al. Calorie restriction (CR) and CR mimetics for the prevention and treatment of age-related eye disorders. Exp Gerontol. 2013;48:1096–100.23588119 10.1016/j.exger.2013.04.002
200. Wang K Li D Sun F Dietary caloric restriction may delay the development of cataract by attenuating the oxidative stress in the lenses of Brown Norway rats Exp Eye Res 2004 78 151 8 10.1016/j.exer.2003.07.009 14667836
Wang K, Li D, Sun F. Dietary caloric restriction may delay the development of cataract by attenuating the oxidative stress in the lenses of Brown Norway rats. Exp Eye Res. 2004;78:151–8.14667836 10.1016/j.exer.2003.07.009
201. Abe T Nakajima A Satoh N Ohkoshi M Sakuragi S Koizumi A Suppression of experimental autoimmune uveoretinitis by dietary calorie restriction Jpn J Ophthalmol 2001 45 46 52 10.1016/S0021-5155(00)00303-8 11163045
Abe T, Nakajima A, Satoh N, Ohkoshi M, Sakuragi S, Koizumi A. Suppression of experimental autoimmune uveoretinitis by dietary calorie restriction. Jpn J Ophthalmol. 2001;45:46–52.11163045 10.1016/S0021-5155(00)00303-8
202. Li Y Wolf NS Effects of age and long-term caloric restriction on the aqueous collecting channel in the mouse eye J Glaucoma 1997 6 18 22 10.1097/00061198-199702000-00005 9075076
Li Y, Wolf NS. Effects of age and long-term caloric restriction on the aqueous collecting channel in the mouse eye. J Glaucoma. 1997;6:18–22.9075076 10.1097/00061198-199702000-00005
203. Obin M Pike A Halbleib M Lipman R Taylor A Bronson R Calorie restriction modulates age-dependent changes in the retinas of Brown Norway rats Mech Ageing Dev 2000 114 133 47 10.1016/S0047-6374(00)00096-8 10799710
Obin M, Pike A, Halbleib M, Lipman R, Taylor A, Bronson R. Calorie restriction modulates age-dependent changes in the retinas of Brown Norway rats. Mech Ageing Dev. 2000;114:133–47.10799710 10.1016/S0047-6374(00)00096-8
204. Izuta Y, Imada T, Hisamura R, Oonishi E, Nakamura S, Inagaki E, et al. Ketone body 3-hydroxybutyrate mimics calorie restriction via the Nrf2 activator, fumarate, in the retina. Aging Cell. 2018;17.
205. Li D Sun F Wang K Protein profile of aging and its retardation by caloric restriction in neural retina Biochem Biophys Res Commun 2004 318 253 8 10.1016/j.bbrc.2004.04.022 15110781
Li D, Sun F, Wang K. Protein profile of aging and its retardation by caloric restriction in neural retina. Biochem Biophys Res Commun. 2004;318:253–8.15110781 10.1016/j.bbrc.2004.04.022
206. Neufeld AH Gachie EN The inherent, age-dependent loss of retinal ganglion cells is related to the lifespan of the species Neurobiol Aging 2003 24 167 72 10.1016/S0197-4580(02)00059-3 12493562
Neufeld AH, Gachie EN. The inherent, age-dependent loss of retinal ganglion cells is related to the lifespan of the species. Neurobiol Aging. 2003;24:167–72.12493562 10.1016/S0197-4580(02)00059-3
207. Obin M Halbleib M Lipman R Carroll K Taylor A Bronson R Calorie restriction increases light-dependent photoreceptor cell loss in the neural retina of fischer 344 rats Neurobiol Aging 2000 21 639 45 10.1016/S0197-4580(00)00165-2 11016532
Obin M, Halbleib M, Lipman R, Carroll K, Taylor A, Bronson R. Calorie restriction increases light-dependent photoreceptor cell loss in the neural retina of fischer 344 rats. Neurobiol Aging. 2000;21:639–45.11016532 10.1016/S0197-4580(00)00165-2
208. Kawashima M Kawakita T Okada N Ogawa Y Murat D Nakamura S Calorie restriction: a new therapeutic intervention for age-related dry eye disease in rats Biochem Biophys Res Commun 2010 397 724 8 10.1016/j.bbrc.2010.06.018 20537981
Kawashima M, Kawakita T, Okada N, Ogawa Y, Murat D, Nakamura S, et al. Calorie restriction: a new therapeutic intervention for age-related dry eye disease in rats. Biochem Biophys Res Commun. 2010;397:724–8.20537981 10.1016/j.bbrc.2010.06.018
209. Zhuang J, Liu J, Gao X, Li H. Inhibition of proliferation in U937 cells treated by blue light irradiation and combined blue light irradiation/drug. Int J Mol Sci. 2018;19:1464–75.
210. Godley BF Shamsi FA Liang FQ Jarrett SG Davies S Boulton M Blue light induces mitochondrial DNA damage and free radical production in epithelial cells J Biol Chem 2005 280 21061 6 10.1074/jbc.M502194200 15797866
Godley BF, Shamsi FA, Liang FQ, Jarrett SG, Davies S, Boulton M. Blue light induces mitochondrial DNA damage and free radical production in epithelial cells. J Biol Chem. 2005;280:21061–6.15797866 10.1074/jbc.M502194200
211. Choi JH Li Y Kim SH Jin R Kim YH Choi W The influences of smartphone use on the status of the tear film and ocular surface PLoS ONE 2018 13 e0206541 10.1371/journal.pone.0206541 30379901
Choi JH, Li Y, Kim SH, Jin R, Kim YH, Choi W, et al. The influences of smartphone use on the status of the tear film and ocular surface. PLoS ONE. 2018;13:e0206541.30379901 10.1371/journal.pone.0206541
212. Lin X Shaw PC Sze SC Tong Y Zhang Y Dendrobium officinale polysaccharides ameliorate the abnormality of aquaporin 5, pro-inflammatory cytokines and inhibit apoptosis in the experimental Sjogren’s syndrome mice Int Immunopharmacol 2011 11 2025 32 10.1016/j.intimp.2011.08.014 21890001
Lin X, Shaw PC, Sze SC, Tong Y, Zhang Y. Dendrobium officinale polysaccharides ameliorate the abnormality of aquaporin 5, pro-inflammatory cytokines and inhibit apoptosis in the experimental Sjogren’s syndrome mice. Int Immunopharmacol. 2011;11:2025–32.21890001 10.1016/j.intimp.2011.08.014
213. Bai J Cervantes C Liu J He S Zhou H Zhang B DsbA-L prevents obesity-induced inflammation and insulin resistance by suppressing the mtDNA release-activated cGAS-cGAMP-STING pathway Proc Natl Acad Sci USA 2017 114 12196 201 10.1073/pnas.1708744114 29087318
Bai J, Cervantes C, Liu J, He S, Zhou H, Zhang B, et al. DsbA-L prevents obesity-induced inflammation and insulin resistance by suppressing the mtDNA release-activated cGAS-cGAMP-STING pathway. Proc Natl Acad Sci USA. 2017;114:12196–201.29087318 10.1073/pnas.1708744114
214. Dham D Roy B Gowda A Pan G Sridhar A Zeng X 4-Hydroxy-2-nonenal, a lipid peroxidation product, as a biomarker in diabetes and its complications: challenges and opportunities Free Radic Res 2021 55 547 61 10.1080/10715762.2020.1866756 33336611
Dham D, Roy B, Gowda A, Pan G, Sridhar A, Zeng X, et al. 4-Hydroxy-2-nonenal, a lipid peroxidation product, as a biomarker in diabetes and its complications: challenges and opportunities. Free Radic Res. 2021;55:547–61.33336611 10.1080/10715762.2020.1866756
215. Wang W Wu RD Chen P Xu XJ Shi XZ Huang LH Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta-cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes Diab Metab Res Rev 2020 36 e3212 10.1002/dmrr.3212
Wang W, Wu RD, Chen P, Xu XJ, Shi XZ, Huang LH, et al. Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta-cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes. Diab Metab Res Rev. 2020;36:e3212.10.1002/dmrr.3212
216. Deng X Yang G Zheng X Yang Y Qin H Liu ZX Plasma mtDNA copy numbers are associated with GSTK1 expression and inflammation in type 2 diabetes Diabet Med 2020 37 1874 8 10.1111/dme.14132 31502701
Deng X, Yang G, Zheng X, Yang Y, Qin H, Liu ZX, et al. Plasma mtDNA copy numbers are associated with GSTK1 expression and inflammation in type 2 diabetes. Diabet Med. 2020;37:1874–8.31502701 10.1111/dme.14132
217. Liu H Gambino F Jr Algenio CS Wu C Gao Y Bouchard CS Inflammation and oxidative stress induced by lipid peroxidation metabolite 4-hydroxynonenal in human corneal epithelial cells Graefes Arch Clin Exp Ophthalmol 2020 258 1717 25 10.1007/s00417-020-04647-2 32445015
Liu H, Gambino F Jr, Algenio CS, Wu C, Gao Y, Bouchard CS, et al. Inflammation and oxidative stress induced by lipid peroxidation metabolite 4-hydroxynonenal in human corneal epithelial cells. Graefes Arch Clin Exp Ophthalmol. 2020;258:1717–25.32445015 10.1007/s00417-020-04647-2
218. Yang L Sui W Li Y Qi X Wang Y Zhou Q Substance P inhibits hyperosmotic stress-induced apoptosis in corneal epithelial cells through the mechanism of Akt activation and reactive oxygen species scavenging via the neurokinin-1 receptor PLoS ONE 2016 11 e0149865 10.1371/journal.pone.0149865 26901348
Yang L, Sui W, Li Y, Qi X, Wang Y, Zhou Q, et al. Substance P inhibits hyperosmotic stress-induced apoptosis in corneal epithelial cells through the mechanism of Akt activation and reactive oxygen species scavenging via the neurokinin-1 receptor. PLoS ONE. 2016;11:e0149865.26901348 10.1371/journal.pone.0149865
219. Lv Y Chu C Liu K Ru Y Zhang Y Lu X A combination of CMC and alpha-MSH inhibited ROS activated NLRP3 inflammasome in hyperosmolarity stressed HCECs and scopolamine-induced dry eye rats Sci Rep 2021 11 1184 10.1038/s41598-020-80849-2 33441928
Lv Y, Chu C, Liu K, Ru Y, Zhang Y, Lu X, et al. A combination of CMC and alpha-MSH inhibited ROS activated NLRP3 inflammasome in hyperosmolarity stressed HCECs and scopolamine-induced dry eye rats. Sci Rep. 2021;11:1184.33441928 10.1038/s41598-020-80849-2
220. Ali S, Davinelli S, Mencucci R, Fusi F, Scuderi G, Costagliola C, et al. Crosslinked hyaluronic acid with liposomes and crocin confers cytoprotection in an experimental model of dry eye. Molecules. 2021;26:849–57.
221. Li J Ruzhi D Hua X Zhang L Lu F Coursey TG Blueberry component pterostilbene protects corneal epithelial cells from inflammation via anti-oxidative pathway Sci Rep 2016 6 19408 10.1038/srep19408 26762881
Li J, Ruzhi D, Hua X, Zhang L, Lu F, Coursey TG, et al. Blueberry component pterostilbene protects corneal epithelial cells from inflammation via anti-oxidative pathway. Sci Rep. 2016;6:19408.26762881 10.1038/srep19408
222. Thacker M, Tseng CL, Chang CY, Jakfar S, Chen HY, Lin FH. Mucoadhesive Bletilla striata polysaccharide-based artificial tears to relieve symptoms and inflammation in rabbit with dry eyes syndrome. Polymers. 2020;12:1465–82.
223. Choi W Lee JB Cui L Li Y Li Z Choi JS Therapeutic efficacy of topically applied antioxidant medicinal plant extracts in a mouse model of experimental dry eye Oxid Med Cell Longev 2016 2016 4727415 10.1155/2016/4727415 27313829
Choi W, Lee JB, Cui L, Li Y, Li Z, Choi JS, et al. Therapeutic efficacy of topically applied antioxidant medicinal plant extracts in a mouse model of experimental dry eye. Oxid Med Cell Longev. 2016;2016:4727415.27313829 10.1155/2016/4727415
224. Choi W Kim JC Kim WS Oh HJ Yang JM Lee JB Clinical effect of antioxidant glasses containing extracts of medicinal plants in patients with dry eye disease: a multi-center, prospective, randomized, double-blind, placebo-controlled trial PLoS ONE 2015 10 e0139761 10.1371/journal.pone.0139761 26457673
Choi W, Kim JC, Kim WS, Oh HJ, Yang JM, Lee JB, et al. Clinical effect of antioxidant glasses containing extracts of medicinal plants in patients with dry eye disease: a multi-center, prospective, randomized, double-blind, placebo-controlled trial. PLoS ONE. 2015;10:e0139761.26457673 10.1371/journal.pone.0139761
225. Amico C Tornetta T Scifo C Blanco AR Antioxidant effect of 0.2% xanthan gum in ocular surface corneal epithelial cells Curr Eye Res 2015 40 72 6 10.3109/02713683.2014.914542 24832134
Amico C, Tornetta T, Scifo C, Blanco AR. Antioxidant effect of 0.2% xanthan gum in ocular surface corneal epithelial cells. Curr Eye Res. 2015;40:72–6.24832134 10.3109/02713683.2014.914542
226. Cavet ME Harrington KL Vollmer TR Ward KW Zhang JZ Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells Mol Vis 2011 17 533 42 21364905
Cavet ME, Harrington KL, Vollmer TR, Ward KW, Zhang JZ. Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells. Mol Vis. 2011;17:533–42.21364905
